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Abstract 
The immune status of an individual host or among a population is affected by important 
variables including the source and route of potential natural exposure and for vaccination consist 
of vaccine type, potency, and virus strain; vaccination route and schedule; and individual host 
factors. Although, perhaps, often overlooked, it is essential to have a basic understanding of the 
laboratory methods used to measure and assess the host’s immune status. The precision, 
accuracy, sensitivity, and specificity of a method must be well defined. Moreover, an “adequate,” 
acceptable, or diagnostic value for each method must be clearly defined so that a particular test 
result for a patient can be meaningfully interpreted in relation to the patient’s history and clinical 
management. The reasons for performing rabies serology can range from diagnosis of infection 
to investigation of epitope specificity of an anti-rabies virus glycoprotein monoclonal antibody. 
Characterization of an antibody’s affinity, specificity, quantity, and neutralizing function, and 
class/subclass are achieved by various methods. Many serological techniques developed over the 
past five decades differ not only in their ability to detect the function, affinity and specificity of 
rabies virus antibodies, but also in the ease and practicality with which they are performed. To 
select an appropriate method and appropriately interpret test results, it is essential to understand 
the specific strengths, weaknesses, and limitations of available methods. The decision to use a 
specific assay should start with the purpose of testing and the intended application of results. 
Other factors to consider are the assay complexity, degree of precision and/or accuracy, 
specificity and range of detection. Given the importance of RVNA levels in the prevention of 
human and animal rabies, guidelines for adequate vaccination should be stated in terms that are 
readily understood by individuals-at-risk and health care providers, both veterinary and medical, 
who will use the recommendations for clinical management of humans or animals. Across the 
  
globe, the standardization of rabies serologic assays has a direct effect on the clinical use of 
human and animal products, including direct assessment of, and assessment of host responses to, 
rabies vaccines for the prevention of rabies. 
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Chapter 1 - Literature Review 
Introduction 
 
 
 
 
There are a number of variables to be considered in the assessment of immune status of 
an individual host or among a population. For a pathogen like rabies virus, important variables 
include the source and route of potential natural exposure and for vaccination consist of vaccine 
type, potency, and virus strain; vaccination route and schedule; and individual host factors. 
Although perhaps often overlooked, it is essential to have a basic understanding of the laboratory 
methods used to measure and assess the host’s immune status. The precision, accuracy, 
sensitivity, and specificity of a method must be well defined. Moreover, an “adequate,” 
acceptable, or diagnostic value for each method must be clearly defined so that a particular test 
result for a patient can be meaningfully interpreted in relation to the patient’s history and clinical 
management. If these parameters are not clearly and objectively defined, conclusions based on 
test results from various methods may be inherently misleading. If a laboratory method such as 
the rapid fluorescent focus inhibition test (RFFIT) (Smith, Yager, & Baer, 1973) developed for 
measuring vaccine response in serum samples is applied for the analysis of biologic products 
such as human or equine rabies immune globulin (RIG) or rabies virus neutralizing monoclonal 
antibodies, the method will most likely need modifications and thus also subsequent method 
validation. 
“Measurements are the basis of science.  
Therefore the methods used to assess immunological parameters and 
immunity…… need to be critically reviewed.  
Is the chosen parameter accurately measured, is it robust,  
is it a good correlate of protective immunity…..?”  
(Zinkernagel, 2002) 
 
2 
Serology is the study of the immunological properties of blood serum or other bodily 
fluids. For the most part, serology is the investigation of antibodies in serum, although 
assessment of immunity may be conducted on cerebrospinal fluid and other sources of fluid. 
Antibodies are produced by plasma cells which may be specifically activated in response to 
antigens, such as those from viruses and bacteria, to protect the host. The primary action of an 
antibody is to bind to antigen. The secondary or effector actions of antibodies include 
neutralization and opsonization of infectious agents, and activation of other immune mediators 
(see Figure 1.1). Complement activation and antibody dependent cellular cytotoxity (ADCC) are 
other effector functions that rely on the binding action of antibodies. Not all antibodies have 
effector actions. Some antibodies that bind to an antigen may not result in a biological effect 
because they are not effective in eliciting a secondary effect. Effector actions occur in 
accordance with the individual characteristics of a specific antibody structure and depend upon 
the class, subclass, or variable region of an antibody. In a competent host, exposure to an antigen 
will activate multiple immune cell clones and result in the production of a polyclonal antibody 
response. 
3 
 
Figure 1.1  The effector functions of antibodies include: A. activation of immune cells such as 
macrophages to produce cytokines and chemokines through Fc receptor binding; B. 
Opsonization of infectious organisms induces phagocytosis of the organisms through Fc receptor 
binding; and C. Neutralization of virus though binding of proteins used for attachment and entry 
of the virus, thereby blocking infection of the cell. 
 
4 
Rabies virus specific antibodies are produced by the immune system in response to 
infection or vaccination in vivo, or by immune cells or molecular methods in vitro. The reasons 
for performing rabies serology can range from diagnosis of infection to investigation of epitope 
specificity of an anti-rabies virus glycoprotein monoclonal antibody. Characterization of an 
antibody’s affinity, specificity, quantity, and neutralizing function, complement binding function, 
and class/subclass are achieved by various methods. Many serological techniques developed over 
the past five decades differ not only in their ability to detect the function, affinity and specificity 
of rabies virus antibodies, but also in the ease and practicality with which they are performed. To 
select an appropriate method and appropriately interpret test results, it is essential to understand 
the specific strengths, weaknesses, and limitations of available methods. Numerous reports 
indicate that protection against rabies is largely dependent upon the presence of rabies virus 
neutralizing antibodies (RVNA) (Hooper et al., 1998; Dietzschold, 1993). Thus, assays to detect 
and quantify RVNA, such as the rapid fluorescent focus inhibition test (RFFIT) (Smith et al., 
1973) and the fluorescent antibody virus neutralization test (FAVN) (Cliquet, Aubert, & Sagne, 
1998) are the methods recommended for quantitation purposes in rabies serology. Antigen 
binding assays have proven to be useful for the detection of specific isotypes of rabies virus 
antibodies, either using whole virions or specific viral proteins as antigen(s). The decision to use 
a specific assay should start with the purpose of testing and the intended application of results. 
Other factors to consider are the assay complexity, degree of precision and/or accuracy, 
specificity and range of detection. In addition, the availability of laboratory materials, 
instruments, and safety equipment also must be considered. It is critical to understand exactly 
what aspect of rabies virus specific antibodies are measured as well as the limitation of the assay 
in order to select the best test and also interpret and use the test results in an appropriate manner. 
5 
Investigative serology focuses on the detection and measurement of immune components 
in blood (usually serum) including immunoglobulins of several subclasses directed against 
specific epitopes. Detection of IgM and IgG classes is dependent upon the time point in the 
course of the humoral immune response after exposure to an antigen. In the initial or primary 
antibody response, IgM is produced first in relatively low levels followed by higher levels of IgG 
after the occurrence of class switching. If the purpose of the assay is to detect the initial 
response, it should be designed to detect both IgM and IgG. The specificity of the 
immunoglobulin produced is driven by distinct epitopes present on the rabies viral proteins used 
to generate the antibodies. Exposure to rabies virus, whether through vaccination with 
inactivated virus or through exposure, induces the formation of antibodies potentially against all 
viral proteins, but predominantly against the rabies virus glycoprotein (G) and nucleoprotein (N). 
Studies of monoclonal antibodies (Mabs) capable of neutralizing rabies virus indicate that these 
Mabs are directed against a number epitopes on the G of rabies virus (Tordo, 1996).  
Rabies virus neutralization requires a minimum number of antibody molecules per G 
spike to induce steric hindrance of the virus-receptor-binding activity (Flamand, Raux, Gaudin, 
& Ruigrok, 1993). Another mechanism may involve conformational changes in the G protein 
ultimately resulting in the loss of virion receptor-binding ability (Irie & Kawai, 2002). The 
humoral immune response elicited by rabies virus vaccination consists of a mixture of polyclonal 
antibodies that influence a variety of complex neutralization mechanisms.  
Specific methods to detect antibodies specific for rabies viral antigens include 
precipitation, agglutination, immunoelectrophoresis, radioimmunoassay, enzyme-linked 
immunosorbent assays (ELISA), Western blots, indirect immunofluorescence, immunoelectron 
microscopy and serum neutralization assays. All of these assays depend on an antibody–antigen 
6 
interaction to detect the presence of an antibody. Two basic types of assays are used: 1) assays 
involving primary binding activity between antibodies and antigens, and 2) functional assays to 
measure neutralization actions of antibodies. Although other components and products of the 
immune system are involved, protection from clinical rabies after infection relies heavily on the 
presence of RVNA. Therefore, methods to detect and quantify antibodies which can functionally 
neutralize rabies virus are recommended to quantify the level of immunity after rabies 
vaccination.  
 History of Regulatory Standards 1.1
Throughout history, various governmental entities have been responsible for regulating 
drug products and related methods for human health assessment. This has and continues to 
include measures of rabies immunity in relation to diagnosis, qualification of biologic products 
such as vaccines and rabies immune globulins, and response to vaccination, particularly in at-risk 
groups. The primary function of government regulation has been to ensure the quality and safety 
of drug products available for human use. Federal regulations began on a large scale in the early 
twentieth century when the U.S. Congress enacted the Pure Food and Drugs Act of 1906. The 
Food and Drug Administration (FDA) was born from this law and has oversight over products, 
marketing of food and drugs to consumers, and the manufacturing practices of food and drug 
industrial companies.  
Most major regulatory standards throughout history arose from disasters. In 1976, Good 
Laboratory Practices (GLP) were created by FDA in response to a high percentage of studies 
with flawed data, falsified data, insufficient documentation, inappropriate testing facilities, and 
instances where experimental animals were subjected to inhumane conditions. In the 1970's, the 
Organization for Economic Co-operation and Development was created to ensure quality, 
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integrity, and reproducibility of data, a global definition of GLP. Good Manufacturing Practices 
(GMP) was created in 1972 in response to the Davenport Disaster in which six people died due 
to contaminated intravenous fluids. Good Clinical Practices (GCP) began at the end of World 
War II following inhumane experiments performed on humans prompting the Nuremberg Code, 
which outlines the proper means to conduct research.  These instructions were the foundation of 
GCP (Milestones in US Food and Drug Law History, FDA, (2009)). Each standard has been 
updated continually to meet the growing demands of ensuring safety and the quality of drug 
research and clinical trials. Throughout the 70's and 80's, Japan, the UK and other European 
countries had developed their own set of GCP guidelines. Different guidelines developed and put 
in place in each individual country brought into question the validity of clinical trials performed 
in different countries. In 1996, conferences were held to unify each country’s GCP codes of 
practice resulting in the "International Conference on Harmonization of Good Clinical Practice" 
ICH-GCP (Baynes, 2005).  The International Conference on Harmonisation (ICH) of Technical 
Requirements for Registration of Pharmaceuticals for Human Use (1996) Guideline for Good 
Clinical Practice E6(R1) is available online from: 
http://www.ich.org/LOB/media/MEDIA482.pdf (Accessed: 08 October 2010). 
 Regulatory requirements  1.2
Research is the cornerstone of all scientific endeavors. It is a harnessing of curiosity to 
solve new or existing problems, prove new ideas, or develop new theories. Research is not 
defined or controlled. No formal regulatory requirements exist for laboratory assay development 
or performance for scientific research. Primary regulations dealing with clinical laboratories like 
the Clinical Laboratory Improvement Amendments (CLIA) or the College of American 
Pathologists (CAP) specifically state that they do not have jurisdiction over research. The FDA 
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does not provide regulations for oversight of research testing. Even without regulatory guidance, 
researchers can and do produce work of the highest quality. However, any technology such as: 
new test methods, new vaccines, or prophylactic drugs, that may be developed in an academic 
setting, and eventually transferred to the industrial world must meet quality criteria in order to 
have any commercial potential. So can the 'assurance of quality' needed for regulatory 
compliance be found within basic research?  
The answer to this question is based upon an understanding of what 'assurance of quality' 
is needed for a researcher to test at a level compliant with “Good Practices” as described for 
laboratory, clinical or manufacturing environments, and designated as GLP, GCP or GMP or 
implying any or all of the three by GxP, which GxP represents the abbreviations of these titles 
where x (a common symbol for a variable) represents the specific regulation. First, it must be 
understood what is meant by 'assurance of quality' as defined within a GxP environment. Second, 
it is critical to understand when to apply the different GxP regulations within the research and 
development applied to the prevention or treatment of a disease.  
The fundamental of any requirement or standard is a complete and operational quality 
system that will demonstrate that there is overall control of all aspects of testing and quality. 
Components of a Quality System include but are not limited to the following: the study 
regulations or quality standards of the regulatory body, the testing and standard operational 
procedures (SOPs), the  organization infrastructure with roles and responsibilities (i.e., study 
directory QA, testing personnel, management), trained and competent testing personnel, 
personnel safety, physical facilities, validated/calibrated equipment, validated testing procedures, 
certified reference materials, quality control programs (proficiency testing, conformation testing, 
quality control samples), an internal audit program, laboratory information systems, and 
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procedures for recording and archiving of data (Food and Drug Administration, 1996). These 
standards, if implemented within the laboratory, allow optimal laboratory operations to ensure 
consistent, reproducible, auditable, and reliable laboratory results of a sufficient quality for 
regulatory testing. Complete documentation is required to allow reconstruction of the events not 
only during and right after completion of the study, but also 5-10 or more years later. A quality 
system must be intentionally included in the study or testing process before it starts, and 
monitored and documented during its performance. Quality cannot be created after the work has 
been completed. 
 
Figure 1.2 Drug development is delineated into specific stages, each with its own requirement of 
regulatory oversight. 
 
With the importance of producing quality products and processes and the increase in 
regulatory scrutiny of all aspects of product development and the manufacturing cycle, 
researchers must understand what regulatory environment is applicable for each phase (see 
Figure 1.2) of the development of a product. Researchers need to have an organized approach to 
applying and/or combining the GXP functions.  
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In a rabies research environment, all information and data collected during the basic 
research stage may be inadmissible in the regulatory findings if not obtained through a quality 
system in compliance with GxP regulations. The quality system in place while the research is 
being performed will dictate whether the information and data will be suitable for regulatory 
evaluation. Table 1.1 details the regulatory requirements that must be complied with for 
particular products under development.  
The intended use of the data to be generated will define the recommended regulatory 
level of testing for a product or drug. During the first few stages of drug or treatment studies, 
including basic research to drug discovery, oversight is not provided by any regulatory agency as 
shown in Figure 1.3. During the preclinical development stage, compliance with GLP is required 
(2011). GLP is only relevant to non-clinical (human) testing and deals with the organization, 
processes and conditions under which these studies are planned, performed, monitored, recorded 
and reported. The primary purpose of these (non-human evaluations) studies is generally safety 
testing for the drug and/or product. Clinical evaluation in humans would follow successful safety 
studies. During the human testing phase, GCP is the basis for quality standards and regulatory 
compliance. GCP addresses source data for clinical trials and applies to human research studies 
where the rights, integrity and confidentiality of trial subjects are protected. Within the US, GCP 
used to support human diagnostics and health-care are established by Centers for Medicare & 
Medicaid Services (CMS) regulations and accrediting organizations such as Clinical laboratory 
Improvement Amendments (CLIA).  GCP must be instituted in all laboratory testing during the 
clinical trials from Phase I (to demonstrate tolerance of the test drug and to define human 
pharmacokinetics), through Phase II (where the dose–effect relationship is confirmed), to Phase 
III (full-scale, often multicenter, clinical efficacy trials in hundreds and thousands of patients). 
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The final phase is manufacturing. Any laboratory testing preformed on the manufactured product 
and the actual manufacturing of the product will be completed in compliance with GMP 
standards. These regulations and instructions are covered in FDA, Code of Regulations Title 21.  
Table 1.1 Regulatory Requirements – Laboratory Testing 
Type of Testing Applicable Regulatory Standard 
Drug Product GMP 
Drug Product in Animals GLP 
Human Specimens/Trials GCP/CLIA 
Non clinical safety studies 
development of drugs 
GLP 
Basic research Non-Regulated Testing 
Studies to develop new analytical 
methods 
Non-Regulated Testing 
Discovery of drug product Non-Regulated Testing 
Discovery of disease Non-Regulated Testing 
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Figure 1.3 The intended use of the data to be generated will define the recommended regulatory 
level of testing for a product or drug.  
Test method development is essential to ensure reproducible and defensible data, and 
thus, product quality. A test method must be developed and validated for use to analyze samples 
during the early development of a drug produced. As the drug development progresses from 
nonclinical study through clinical trials to commercialization, the test method will need to follow 
a similar progression. Throughout the process of drug research and test development, method 
validation and revalidation must be considered. Method validation is defined by all regulatory 
standards as to which components must be tested, the acceptance criteria for each component and 
the test method. GXP requirements do not specifically state what components or to what degree 
method validation must be completed during the phases of drug production. The reason is due to 
the fact that drug products and test methods will necessarily evolve through the course of product 
development. The purpose of the assay is linked to the type of trial and the drugs intended 
purpose. As an example (GLP and GMP), the FDA regulation 21 CFR 211.194(a)(2) specifically 
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states that users of analytical methods in the U.S. Pharmacopeia/National Formulary (USP/NF) 
are not required to validate the accuracy and reliability of these methods, but merely verify their 
suitability under actual conditions of use. However, if testing within a clinical trial setting, CLIA 
or ICH regulations would be utilized depending upon the requests or needs of the company 
sponsoring the testing. CLIA specifically states how an assay is to be validated for use. FDA 
regulation CFR Section 493.1253 Standard: Establishment and Verification of Performance 
Specifications states the performance characteristics: accuracy, precision, analytical specificity, 
analytical sensitivity  to include interfering substances, reportable range of test results for the test 
system, verify the reference intervals (normal values), determine calibration and control 
procedures and documentation of all activities specified above (1992). In ICH Q7A: “Changes 
are expected during development, and every change in product, specifications, or test procedures 
should be recorded adequately” (ICH, 2001). Above all else, method validation must prove the 
test method is fit for the purpose of the testing to which it is applied. The performance 
characteristics such as sensitivity, specificity, accuracy, precision, lower limit of detection, 
linearity, and reproducibility for each testing method must be analyzed. It is the laboratory’s 
responsibility to prove suitability or competency of the test method ‘in house’ before and during 
testing. It is possible that a method that functions satisfactorily in one laboratory, fails to operate 
in the same manner in another. It is considered unacceptable for the researcher/laboratorian to 
use a published ‘validated method’ without demonstrating their capability in the use of the 
method (AOAC International, 2002). 
The extent of and expectations from early phase method validation are lower than the 
requirements in the later stages of development. The validation exercise becomes larger and 
more detailed and collects a larger body of data to ensure that the method is robust and 
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appropriate for use at the commercial site. The final method must be validated for the intended 
use whether it is to test the actual product or test the product in use. During the research and 
testing process, partial or full method validation may be required. Logically any assay whether it 
is fully or partially validated must be scientifically sound, suited for its intended purpose and 
stage of product or drug development, and capable of generating reliable results. Any method 
that is newly developed must always be fully validated first prior to being used within a 
laboratory.  
To adapt a quality system within the research stage, the technician performing the testing 
must have the scientific and technical understanding, knowledge of the product (drug, vaccine, 
etc.), and the ability to execute the quality functions of analytical method validation. All 
technicians performing the testing must have appropriate training to promote an understanding of 
the testing principles involved with the method validation, proper documentation of the data as 
well as understanding of how to interpret the data, and an understanding of the cross-functional 
relationships of the testing, product, companies, and patients. This means that fundamental 
quality system components must be applied at the bench level. 
 Assuring Quality Results 1.3
The only way to know if a method has the performance characteristics that “fit the 
purpose” for which it will be used is to define the test method through validation. Just as there 
are consequences for selecting an unsuitable assay for a given purpose, erroneous conclusions 
can be made if the capabilities and limitations of the assay are not considered when interpreting 
results. A method with acceptable accuracy and precision levels for measurement of antibodies 
in a potency range of 0.1 to 10.0 IU/mL in a serum matrix cannot claim the same accuracy and 
precision levels for higher potency samples or samples in a different matrix or body fluid without 
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validation experiments to evaluate these adaptations of the method. The method parameters 
important for a qualitative assay are sensitivity, specificity, and predictive value. In addition to 
sensitivity and specificity, a quantitative assay requires definition of accuracy (closeness to the 
true value), precision (repeatability of the measure), linearity, and reportable range. Recent 
publications are examples of RFFIT or modified RFFIT validations performed for specific 
purposes—evaluation of clinical trial samples for a human monoclonal antibody combination for 
the post-exposure treatment of rabies and vaccine potency evaluation (Kostense et al., 2012; 
Kramer, Bruckner, Daas, & Milne, 2010). Robustness evaluation describes the ability of the 
method to perform to set criteria during normal laboratory conditions, including normal 
variations of equipment performance, reagent lots, or between different personnel. Biologic 
variation must be considered separately from analytical variation. For example, two test results 
from the same sample may vary solely on the basis of the receptivity of cells to virus infection; 
cells used last week may have different virus infectivity characteristics than the cells used in 
subsequent testing. The variation from these types of factors is separate from other sources of 
variation. For repeat measures of the same sample, there are statistical tools to set the expected 
variance and for determining what variance is evidence of a significant difference, such as 
minimum significance ratio (MSR) (Khan & Findlay, 2009). Measurement or detection of rabies 
virus antibodies can be influenced by interference. Interference can be caused by cross reacting 
antibodies, non-specific binding, and matrix effect (hemolysis, lipemia, or “dirty” samples, etc.). 
Interference can occur not only with the antibody of interest in the sample but also in the 
interaction of the detected or competing antibodies in the assay. Naturally occurring proteins in 
samples, such as albumins, fibrinogen, and complement factors, can result in assay interference 
(Selby, 1999). Results from samples with interfering factors can be misleading if the effects of 
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these interfering factors are not considered. In most cases, interference will occur at low levels 
and will not cause measurement problems at higher dilutions or in samples with high potency, 
since specific binding is stronger than the weaker interference reaction. When interference is 
suspected or needs to be ruled out, samples may be evaluated by an alternative method in which 
the effect of interfering factors is minimized so that specific activity may be detected and 
measured. 
The lower limit of detection (LOD) is affected by interference and the assay parameters. 
If the purpose of testing is determination of the presence or absence of rabies virus antibodies, 
defining the lowest level of antibodies that an assay can reliably detect is critical. However if the 
ability to accurately and precisely measure low levels of rabies virus antibodies is important, as 
in evaluation of passive rabies virus immunoglobulin levels in post-exposure treatment, then 
defining an assay’s lower limit of quantitation (LLOQ) is required. Cut-off values assigned to an 
assay depend both on the LOD or LLOQ and the purpose of testing. If the application of the 
rabies serology testing is to identify low levels of rabies virus antibodies and exclude false 
negative test results, the cut-off level should be low, but this may yield some false positive test 
results. Conversely, a higher cut-off value (i.e., above a level which might allow some false 
positive test results) would identify only true positive test results which would be acceptable if 
the purpose of the method is to reliably identify only those individuals. The trade-off is that a 
high cut-off level would increase the number of false negatives (i.e., exclude some true positives 
that are low). The probability of false positive and false negatives is related to the precision of 
the assay. Assays with a high variability particularly at the cut-off level would exclude some true 
positive samples with potency values close to the cut-off level and conversely identify some true 
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negatives as positive. Upon repeat testing, these samples could measure either positive or 
negative. 
The matrix of the sample can affect the LOD and LLOQ for a specific method, therefore 
whenever the sample matrix is altered; re-evaluation of this parameter is required. Any change 
that impacts the sensitivity of an assay will also change the LOD. Indeed, any change in the 
procedure or sample may require re-validation to determine the effect on the established 
performance characteristics. Method variations listed in Table 1.2 (for either binding assays or 
neutralization assays) can be used to customize a method for certain purposes, such as 
measurement of antibodies from a particular species, or within a range of potency values, but the 
changes implemented to customize an assay may also result in changes in the performance 
characteristics of a method. 
Table 1.1.2 ‘Fit for Purpose’ method variations that can be applied to neutralization or 
antigen binding assays 
 
Neutralization Assays 
 
Antigen Binding Assays 
Strain of challenge virus  Antigen – virus strain 
Dose of challenge virus Antigen – virus protein(s) 
Cell type       Whole virus 
Serial dilution scheme        Purified protein 
Detection system Detection system 
      Fluorescent-labeled antibody        Species specific or non-species specific 
      Enzyme-labeled antibody        Immunoglobulin specific for class or 
subclass 
      Modified challenge virus  
(ex. Green Fluorescent Protein  insert) 
Platform – slides, plates, or beads 
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Immunity can be measured by different methods. It is natural to compare the results from 
different methods and it is important to consider how the comparison is made. Although it is 
very common to evaluate agreement between methods by a correlation coefficient, conclusions 
based on this value are improper. According to at least one well-known medical statistician, the 
best way to conduct a method comparison is to calculate the “mean and standard deviation of the 
between-method-differences” (Altman, 1991). It is not enough to just generate and examine the 
data, it is essential to apply appropriate statistical tools. A functional understanding of statistics 
or collaboration with a statistician is often essential for these exercises. The application of 
statistics to evaluations of immunoassay performance is a specialized area of competence, and is 
of particular importance when the assay will be used to determine acceptance of biologics 
(Findlay et al., 2000). 
As previously mentioned, there are some critical components that are essential to 
consider, identify, and control to ensure precise and accurate measurements for serum 
neutralization assays, such as strain and dose of challenge virus, cell type, and reference 
standards. For results to be comparable over time from the same laboratory and possibly between 
laboratories, these components must be standardized. Whenever any critical steps or components 
are changed as may be necessary for a specific purpose, the modified method will require re-
validation. A standard reference rabies immune globulin serum (SRIG) provides a defined 
potency standard in international units per mL (IU/mL). By comparison of the SRIG result to the 
test sample result the value of the test sample is standardized and comparable. But if the SRIG 
used is not the same or not calibrated against a known standard, discrepant results can occur (Yu 
et al., 2012). The value of the test sample result is standardized through comparison with the 
SRIG result in that assay at that time. It is essential for the SRIG to be precisely described for 
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each batch of test results. If the standards are not identical or not calibrated against a known 
standard, results cannot be directly compared between assay runs and between laboratories. 
Standard reference serum of equine source may perform differently than human SRIG such that 
batches of test results will yield different values depending upon the control serum (Haase, 
Seinsche, & Schneider, 1985). The potency assigned to a SRIG by one method may not be the 
same in a different method and cannot be automatically assumed. For example, a control serum 
at 0.5 IU/mL in the RFFIT method may perform at 0.7 Equivalent units per mL (EU/mL) in an 
ELISA-based assay. If this standard with a known performance by RFFIT was directly applied as 
the standard for an ELISA and assumed to perform at 0.5 EU/mL, the ELISA results would bias 
toward the exclusion of some samples which might meet a RFFIT 0.5 IU/mL value. Control 
serum such as an SRIG needs to be fully characterized by a new method and its potency needs to 
be assigned in units applicable to that particular method (Moore & Hanlon, 2010). A comparison 
of two international SRIG products in current use, WHO 1
st
 international rabies immune globulin 
and WHO 2
nd
 international rabies immune globulin, over several years show that reference 
serum can lose potency over time, with the 1
st
 RIG lower in potency by 2.5% in 1997 to 19% 
lower in 2012 by RFFIT, yet higher in potency by ELISA (see Table 1.3) illustrates the 
importance of calibration and monitoring of the RIG in use in a particular laboratory and for a 
particular assay. If the challenge virus of an assay is substantially different than the virus source 
for a vaccine, the serologic results from clinical trials may underestimate responses to the 
vaccine (Moore, Ricke, Davis, & Briggs, 2005; Brookes & Fooks, 2006). The same is true for 
antigen binding assays where the virus strain and type (whole or protein) used in the detection 
system should ideally be the same, to obtain the most informative results.  
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Table 1.3 Comparison of the WHO international standard anti-rabies immunoglobulin, human – 
1
st
 and 2
nd
 
 
Laboratory/Year 
Difference in potency 
(WHO 1
st
/WHO 2
nd
) 
Method of Testing: 
FDA/CDC/KSU 
  1997 2.5% lower RFFIT 
 
  KSU 
  2006 12% lower RFFIT  
2006 36% lower FAVN 
2006 22% higher Direct ELISA 
   
2012 19% lower RFFIT 
2012 34% lower FAVN 
2012 15% higher Direct ELISA 
 
 
 
 
Despite the potential negative effect of a change in how a method is performed, there are 
good reasons to introduce variations to a procedure. These may include the need to measure 
rabies virus antibodies from a specific species which may require a change in the detection 
system or the need to measure potency of samples which are beyond the normal linear range of 
testing and hence may require a pre-dilution to achieve a different range of sample dilutions to be 
tested. Method validation reveals the robustness and limitations of assay and its performance 
characteristics. In addition to method validation, conducting continual monitoring of method 
performance increases the chances that potential problems will be quickly identified. Regular 
participation in proficiency programs is one way to monitor performance of the method and also 
assists in the identification of drifts and trends. If good quality control practices are in place, 
results may be comparable between laboratories even when there are differences in procedure. 
For example, nine laboratories performing the RFFIT for different purposes (from +/- screening 
to regulated quantitative measurements) and executing different RFFIT procedures (including 
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SRIG source, virus strain, cell type used) recently participated in a voluntary exchange of an 
informal proficiency panel of samples. All nine laboratories identified the RVNA negative 
sample as below their assigned cut-off and had reported values within two-fold of the average of 
all measurements for the remaining five RVNA positive samples. Even if laboratories are 
following the same protocol and using the same components, the agreement in results for the 
same sample can vary based on method variables related to environment, personnel training and 
equipment performance. In other words, methods can be standardized, but unless the laboratories 
are adhering to the same quality assurance standards, the results may still demonstrate greater 
variability than is ideal. Acceptance criteria for precision and accuracy are different depending 
upon on the type of assay. Cell-based assays, such as serum neutralization, are inherently more 
variable and thus are allowed greater variability than binding assays. The precision of binding 
assays is generally expected to be in the range of 5-20%, while cell-based assays may be allowed 
a precision variability of 30%, and up to 50% (2001; Chaloner-Larsson, Anderson, & Egan, 
1997). In general, for serological titration assays a two-fold difference in replicate measurements 
is commonly recognized as the upper level of reproducibility (Wood & Durham, 1980). The 
precision of an assay should be taken into account when reviewing rabies serology results in 
relation to survival of experimental challenge, inter-laboratory comparisons, and proficiency 
testing, as well as when establishing acceptable levels for proof of sero-conversion or an 
adequate response to rabies vaccination. 
 Assay Selection 1.4
Knowing the specific component of immunity that is the focus of a particular 
investigation is paramount in selection of the suitable assay. Similarly, it is essential to 
understand the performance characteristics of a particular method and its limitations, to 
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determine whether the method can generate appropriate results that can answer a particular 
question. Rabies virus antibodies are measured for several different reasons. The reasons for 
these measurements will influence the requirements for method sensitivity, specificity, precision, 
accuracy, linear range, limit of detection and robustness of the method. The requirements for 
specific reagents, instrumentation or facilities may vary according to the particular methods. The 
consequence of selecting an improper method can be as simple as getting a result that does not 
answer an academic question, thus leading the research down a wrong path; or, as complex as 
providing incomplete or misleading information that will be used to make essential health care 
decisions, whether veterinary or medical, for the prevention of clinical rabies. For example, if 
there is an encephalitis suggestive of clinical rabies, evaluating a sample from a human or animal 
with an assay which can only detect IgG antibodies could be insensitive or misleading because 
IgM antibodies, which are produced before IgG, may remain undetected. Thus, a negative test 
result would be misleading. Besides the consequence of using an unsuitable method for 
individual diagnosis, ambiguous results add potentially incorrect information to the body of data 
compiled for typical antibody responses in rabies patients. 
Laboratory tests for rabies virus antibodies are used for research, human vaccination 
decisions, pet travel permits, wildlife vaccination program evaluations, and pharmaceutical 
product licensure. No one method will be the ideal fit for all purposes. The method that will “fit” 
must be defined by the characteristics of rabies virus antibodies that are most important or by the 
parameter of interest. For example, to research the difference between monoclonal antibodies 
produced against the glycoprotein of the ERA rabies virus strain, a serum neutralization assay is 
essential if the ultimate purpose of the monoclonal is therapeutic. The challenge virus used in the 
serum neutralization assay should be considered. If the purpose of the monoclonal antibody is 
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use as a therapeutic agent, then the challenge virus used should be one that is most closely 
related to the rabies virus variants that are enzootic in the regions where the biologic is intended 
for use. Moreover, if the monoclonal antibody is intended for eventual licensure, the laboratory 
method selected must be an approved, validated method that is recognized by the licensing 
authority. Conversely, if the purpose of the monoclonal antibody is use in diagnostic testing to 
differentiate ERA infected brains from brains infected with other strains, then the method best 
used to illustrate the difference in monoclonal antibodies would be an IFA using ERA infected 
cells. Below are specific assay requirements that apply to some common reasons for measuring 
rabies virus antibodies: 
 Standardized for comparable results between laboratories and over time (clinical trial 
testing, human testing for vaccine response either for post-exposure or pre-exposure, 
oral-bait program evaluation, pet travel) 
 Detection of low levels in an initial response to infection or vaccination/ability to 
measure low levels of IgM and IgG (clinical diagnosis, evaluation of post-exposure 
treatment, some research purposes) 
 Cost effective (to obtain screening results from large numbers of samples) 
 Adaptable for detecting difference immunoglobulin subclasses (research and clinical) 
 Adaptable for detecting specificities or antibodies from difference species (research and 
surveillance) 
 Approved by regulatory authorities (biologic product testing, pet travel) 
 Low technology or low level bio-containment facilities (field research or in areas of 
developing countries) 
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Consideration of the sample is also a factor in choosing the proper assay. Attempting to 
measure a F(ab’)2 product with an ELISA whose secondary detection system relies on binding to 
the Fc portion of the immunoglobulin would be futile. A blocking or competitive ELISA or a 
serum neutralization assay would be a better ‘fit’ for this purpose because these assays do not 
rely on the complete structure of the immunoglobulin, only the antigen binding portion, F(ab’)2 
for detection. In human laboratory medicine, it is not uncommon to screen samples using a 
sensitive assay to identify positive samples from negative samples and then follow the sensitive 
screening tool with confirmatory testing with a more specific assay to identify the true positive 
samples and exclude the false positives. Several methods can be used effectively for screening 
purposes. Depending on the screening goal, assays such as ELISA using whole virus antigen, 
lateral flow with a positive or negative readout, and IFA can identify samples that potentially 
contain rabies virus specific antibodies. Testing with a western blot technique can confirm the 
specificity of the antibodies detected in the screening assay or testing with a serum neutralization 
(SN) method can confirm the neutralizing function of the antibodies. A screening method with 
lower accuracy (result may not be the true value), but higher precision (repeat measurements are 
clustered closely although they may not be near the true value) may be more useful for oral 
baiting surveillance, if it is quick, standardized and simple, than a more accurate method that is 
cumbersome, time-consuming, and more variable. For the purpose of evaluation of oral baiting 
campaigns, determination of individual “protection” is less important than herd immunity levels 
and the ability to confidently compare results between laboratories and over time. 
 Serum Neutralization Assays 1.5
Rabies serum neutralization assays are distinguished by the ability to detect the 
neutralization activity of specific antibodies in vitro and therefore attempts to measure the 
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potential protective action of these antibodies in vivo. Technical performance of rabies virus 
neutralization assays requires the use of infectious virus and can be labor intensive and time 
consuming. There are two rabies serum neutralizing assays recognized by the World Health 
Organization (WHO) and the World Organisation for Animals Health (OIE) to measure RVNA: 
the rapid fluorescent focus inhibition test (RFFIT), described in 1973 by Smith et al. (Smith et 
al., 1973); and the fluorescent antibody virus neutralization test (FAVN), developed in 1997 by 
Cliquet et al. (Cliquet et al., 1998). Measurement of RVNA by serum neutralization assays is 
based on the same principle as the mouse neutralization test (MNT), extensively employed in 
early rabies serology work. The MNT involves the injection of test serum dilutions in mice 
followed by a challenge with a standard dose of rabies virus, with the read-out being mortality 
among the mice (Atanasiu, 1973). While this is truly a “real” measurement of the protective 
function RVNA in the serum, the biological variation of individual mouse immunity as well as 
possible interference of other immune effectors made it difficult to standardize the test. With the 
development of in vitro methods such as the RFFIT, improvements in sensitivity and 
standardization were achieved.  
Both the RFFIT and the FAVN tests consist of incubation of dilutions of heat-inactivated 
serum with a fixed amount of live rabies virus for 60–90 minutes at 37°C. Measurement of 
residual virus infectivity is accomplished by detection of virus in cell culture via a labeled anti-
rabies virus antibody and subsequent calculation of the quantitative titer by the number 
microscopic fields containing virus infected cells. The RFFIT method is conducted in multi-
chamber slides (see Figure 1.4 A). Serum is serially diluted fivefold and tested in each well. 
Variations of the RFFIT include the use of microtiter plates in place of the slides and the use of 
twofold or threefold dilutions. The rabies challenge virus should contain 30–100 50% tissue 
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culture infective dose (TCID50). After the virus is added to the diluted serum, the slides are 
incubated at 37°C for 90 minutes, after which baby hamster kidney (BHK) or mouse 
neuroblastoma (MNA) cells are added to each of the wells. Diethylaminoethyl-Dextran (DEAE-
Dextran) has been used, typically at a 0.01 µg/mL concentration, in some variations of the 
RFFIT to enhance susceptibility of the cells to rabies virus infection (Kaplan, Wiktor, Maes, 
Campbell, & Koprowski, 1967). The slides are generally incubated at 37°C in a 2-5% CO2 
incubator for 20–24 hours, although the incubation period is extended to 48 hours in some 
variations of the method conducted in microtiter plates. The wells containing an adherent 
monolayer of cells are washed and the cells are fixed with 80% cold acetone. FITC-conjugated 
anti-rabies virus antibody directed against the rabies virus nucleoprotein (N) is added in order to 
detect virus-infected cells. In 8-well chamber slides, 20 fields of each well are examined using a 
fluorescent microscope for the presence of fluorescence in the cells, an absence of which 
indicates antibodies in the sample neutralized virus and the presence of which indicates a lack of 
antibodies. The titer of RVNA in the serum sample being analyzed is defined as the dilution at 
which 50% of the observed microscopic fields contain one or more infected cells. Mathematical 
calculation using the Reed and Muench formula, Spearman-Karber formula or Probit method 
will determine the exact quantitative titer of RVNA in the serum sample. Alternatively, the 
quantitative titer of RVNA can be more simply defined, but with less precision, as the highest 
serum dilution where 100% viral inhibition occurred, thus indicating that there were no infected 
cells at that dilution and all subsequent higher dilutions exhibit infected cells (Habel, 1996; 
Aubert, 1996). Transcribing a serum dilution value into a standardized and more globally 
recognized measure of IU/mL is achieved by a simple calculation wherein the value from a 
serum sample being tested is compared to the serum dilution value of a reference serum standard 
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containing a specific amount of RVNA previously tested and verified to be accurate (Velleca & 
Forrester, 1981). The quality of the test components as well as the skill and expertise of the 
technician conducting the test, including the analysis of the microscopic readout, can 
substantially affect the precision of RFFIT test results.  
To simplify and reduce the subjectivity of the microscopic counting step, the FAVN 
method uses four replicates of serum using threefold dilutions in microtiter wells and scores each 
well as either positive or negative for the presence of rabies virus infected cells after a 48-hour 
incubation. A direct comparison of the two methods demonstrated no statistically significant 
differences in results when conducted in a laboratory adhering to good quality assurance 
standards (Briggs et al., 1998). Precision and repeatability of virus neutralization test results can 
be controlled by strict adherence to the dose and strain of the challenge virus used and the source 
of the standard reference serum. Early published reports that compared different laboratory 
RFFIT results reported that the use of a high infective dose of challenge virus resulted in reduced 
sensitivity for testing low titered sera, whereas a low viral dose of challenge virus could result in 
lower precision when testing high titered sera such as rabies virus immunoglobulin (RIG) 
preparations (Fitzgerald, Baer, Cabasso, & Vallancourt, 1975). In addition, the use of an equine 
RIG as the reference standard to determine IU/mL values resulted in significantly different titer 
results than when a human RIG reference standard was used (Lyng, Bentzon, & Fitzgerald, 
1989). Measuring RVNA from people vaccinated with a vaccine prepared with a parent virus 
strain heterologous to the challenge virus strain in the RFFIT (usually CVS-11) can result in 
lower titers than if a homologous challenge strain is used (Moore et al., 2005). Rabies virus 
neutralization tests identify the presence of all classes of immunoglobulin in a sample (both IgM 
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and IgG) and therefore will be able to detect the early production of rabies virus antibody after 
exposure or vaccination, but may not be as sensitive as the IFA (Smith, 1991).  
Because the virus neutralization testing method depends on the measurement of residual, 
or ‘non-neutralized’ rabies virus infecting the cells, the presence of interference factors in the 
sera or culture media that adversely affects cell (and ultimately viral) growth will mimic virus 
neutralization by non-specifically inhibiting viral growth. Any inhibition of viral growth not 
directly due to neutralizing antibody will give a false positive result. As with ELISA techniques, 
some steps of the virus neutralization test can be automated, especially when performed using 
micro-titer plates, (e.g., the addition of media to the plates, serial dilution of the serum samples, 
addition of virus and anti-rabies virus conjugate) as well as some of the more tedious steps such 
as plate washing, allowing the application of these methods to high-throughput testing. 
Automated reading of FAVN and RFFIT reduces the work-time required for the microscopic 
analysis readout and aids in the minimization of errors (Peharpre et al., 1999). No significant 
difference was noted when comparison was made between the rabies virus antibody levels 
reported by automated and non-automated reading, but the automated reading resulted in lower 
sensitivity. The expense of the equipment required to conduct automated reading of the RFFIT or 
FAVN, the requirement for a consistent cell monolayer and need for a good quality FITC 
conjugate limits the practicality of this enhancement, especially for laboratories that do not 
conduct large numbers of tests. As an alternative to microscopic fluorescence measurement, a 
microneutralization test (RAMIN), and  the indirect immunoperoxidase virus neutralization 
(IPVN) technique and the modified FAVN, employ a mouse anti-rabies virus antibody and a 
peroxidase anti-mouse conjugate enabling automated reading by a spectrophotometer (Mannen et 
al., 1987; Cardoso, Silva, Albas, Ferreira, & Perri, 2004; Hostnik, 2000). In each of these studies, 
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a good correlation was confirmed between traditional rabies virus neutralization methods and the 
modifications that were made to each test. Other modifications take advantage of molecular 
techniques to prepare recombinant viruses to use in place of the standard challenge virus, CVS-
11, for standardization of fluorescence or for adaptability to detect different specificities of 
antibodies. Modified CVS-11 expressing green fluorescent protein (GFP), eliminates the need 
for FITC-conjugated anti-rabies virus antibody (Khawplod et al., 2005). Using this modified 
CVS-11 in combination with flow cytometry to detect residual virus present after incubation 
with serum, reportedly increases the sensitivity because each cell is individually assessed for 
viral infectivity, creating a more precise percentage of viral inhibition (Bordignon et al., 2002). A 
new method developed by Wright et. al. (2008) utilizes pseudotype viruses—lentivirus vectors 
expressing rabies virus glycoprotein and a reporter (e.g., lacZ, GFP) (Wright et al., 2008). By 
expressing the glycoprotein from different rabies virus strains, a panel of pseudotypes can be 
used in cross-species comparison studies. Because the pseudoviruses are replication incompetent 
particles, this method is applicable in areas where high level bio-containment facilities are not 
available.  
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Figure 1.4 (A). RFFIT procedure. Serum is serially diluted in a 96 well plate and transferred 
into 8-well chamber slides. The rabies challenge virus is added to the diluted serum, the slides 
are incubated at 37°C for 90 minutes, after which baby hamster kidney (BHK) or mouse 
neuroblastoma (MNA) cells are added to each of the wells. The slides are incubated at 37°C in a 
2-5% CO2 incubator for 20–24 hours. The wells containing an adherent monolayer of cells are 
washed and the cells are fixed with 80% cold acetone. FITC-conjugated anti-rabies virus 
antibody directed against the rabies virus N is added in order to detect virus-infected cells. In 8-
well chamber slides, 20 fields of each well are examined, using a fluorescent microscope, for the 
presence of fluorescence in the cells indicating the presence of non-neutralized rabies virus. The 
titer of RVNA in the serum sample being analyzed is defined as the dilution at which 50% of the 
observed microscopic fields contain one or more infected cells. (B) IFA technique. Test serum 
in added to slides fixed with rabies virus-infected cells. Rabies virus antibodies in the serum bind 
to antigens on rabies virus proteins present in the infected cells and are subsequently detected by 
FITC-labeled anti-IgG or anti-IgM. Slides are read on a fluorescence microscope to evaluate the 
slides for the presence of labeled antibodies.  
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Figure 1.4 (C). Competitive ELISA. A labeled rabies virus antibody competes with the rabies 
virus antibodies in the test sample. The test serum sample and an enzyme-labeled anti-rabies 
virus antibody is incubated with the inactivated rabies virus antigen on the well surface. The 
amount of enzyme-labeled antibody is detected by adding a conjugate for color development; 
amount of rabies virus antibody in the serum sample is inversely related to intensity of color 
development. The level of antibody in the test serum can be quantitated by use of a standard 
curve and an OD reader. (D) Lateral Flow. The test serum sample is mixed with inactivated 
virus before adding the mixture to the absorbent material of the test strip. The mixture then flows 
across to encounter a labeled anti-rabies virus (anti-G) antibody which will bind to any unbound 
inactivated rabies virus. The mixture continues to flow toward two areas (lines) of the strip 
bound with detection antibodies; the first detection antibody is specific for the rabies virus (anti-
G), and the second detection antibody is specific for the labeled rabies virus (anti-G) antibody. If 
the mixture contains unbound inactivated rabies virus there will a color development at the first 
strip, indicating the sample did not contain enough anti-rabies virus antibody to bind the 
inactivated rabies virus in the mixture. If the test serum sample does contain anti-rabies virus 
antibody, then the labeled antibody will pass the first strip and be bound by the antibody in the 
second strip causing a color development at the second strip. The results will be either “presence 
of rabies virus antibody” (only second strip visible) or ‘absence of rabies virus antibody” (first 
and second strip visible).  
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 Binding Assays 1.6
Binding assays are methods that detect or measure immunoglobulin molecules by their 
ability to bind specifically to their target antigen. This binding can be detected by use of 
secondary detection systems usually bound to a color development system for visualization or 
quantitation by optical density (OD) or fluorescent measurement. ELISA assays are the most 
commonly used binding assay. ELISA assays may be based on indirect, competitive, and 
blocking approaches. Other binding assays are lateral flow and indirect fluorescent antibody 
(IFA). Western blots are used to identify the fine specificities of antibodies. Antigen binding 
assays such as ELISAs and IFAs are rapid, simple and often do not require manipulation of 
infectious rabies virus during the assay, although preparation of antigen may involve live virus. 
These assays rely on the interaction of the antibody and antigen, regardless of the ability of the 
antibody to neutralize rabies virus, and are useful for the detection of rabies virus binding 
antibodies. An assay with whole virus as the target antigen may be useful to identify the presence 
of rabies virus antibodies specific for the different antigens on the rabies virus. Conversely, 
purified viral proteins can be used to distinguish the specific composition of antibodies which 
may be present. Binding assays are able to identify the subclass of rabies virus antibodies (for 
example, IgM and IgG) by using a conjugated anti-subclass Ig antibody as the secondary 
antibody.  
The IFA technique involves adding test serum to slides fixed with rabies virus-infected 
cells (see Figure 1.4 B.). Rabies virus antibodies in the serum bind to antigens on rabies virus 
proteins present in the infected cells and are subsequently detected by FITC-labeled anti-IgG or 
anti-IgM. A fluorescence microscope is required to evaluate the slides for the presence of labeled 
antibodies. Quantification of the antibodies can be accomplished by serial dilution of the serum 
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to determine the antibody titer. Because infected cells are used as the source of rabies virus 
antigen, antibodies with specificities to different rabies virus proteins can detected and also 
antibodies to cellular antigens. The possibility of detecting non-rabies of antibody binding that is 
not specific to rabies antigen (i.e., autoantibodies, antibodies to cellular antigens, etc.) is 
important to consider when evaluating the results.  
Early ELISA methods, such as the one described by Nicholson and Prestage in 1982 used 
inactivated whole virus as the antigen and anti-IgG as the secondary antibody (Nicholson & 
Prestage, 1982). This technique offered greater specificity over the IFA since the only source for 
binding is whole virus coated to the surface of the well and not in a cell where there are other 
antigens present as possible targets for interfering antibodies. Modification of the ELISA by 
Grassi in 1989 improved the assay specificity further by using purified rabies virus glycoprotein 
(G) antigen allowing detection of anti-rabies G antibodies (Grassi, Wandeler, & Peterhans, 
1989). In contrast to early ELISA assays, there is a higher degree of correlation between RFFIT 
and G-protein ELISA due to the fact that most neutralizing antibodies are directed against the G 
protein. The secondary antibody employed by ELISA methods may be species specific but if 
staphylococcus Protein A is employed, the method can be applied to samples from a number of 
species because Protein A binds to the Fc portion of the IgG of many species.  
Other types of ELISAs include competitive (cELISA) and blocking ELISA. Both 
methods involve the use of a labeled rabies virus antibody to either compete with (cELISA) or to 
detect antigen not blocked by (blocking ELISA) the rabies virus antibodies in the test sample. In 
the blocking ELISA, incubation of the serum sample with the inactivated rabies virus antigen on 
the well surface is followed by addition of an enzyme-labeled anti-rabies virus antibody. Any 
unbound (unblocked) inactivated rabies virus is bound by the labeled antibody. The amount of 
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enzyme-labeled antibody is detected by adding a conjugate for color development; the amount of 
rabies virus antibody in the serum sample is inversely related to intensity of color development. 
The level of antibody in the test serum can be quantitated by use of a standard curve and an 
optical density (OD) reader. Competition for rabies virus binding between the anti-rabies virus 
antibodies in a serum sample with a labeled-anti-rabies virus monoclonal antibody is the basis of 
the cELISA (see Figure 1.4 C). Similar to the blocking ELISA, the labeled antibody is measured 
and used to determine the level of anti-rabies virus antibody in the sample. Both of these 
methods can reduce the effect of non-specific binding because the antibody that is measured is a 
purified reagent antibody. Use of different reagent monoclonal antibodies in these assays allows 
detection of various specificities of rabies virus antibodies that may be present in the sample (i.e., 
use of a labeled anti-rabies virus N will detect anti-N in the sample and use of a labeled anti-
rabies virus G will detect anti-G in the sample). 
An electrochemiluminescent (ECL) adaption of the blocking ELISA method employs 
microtiter plates fitted with a series of electrodes at the bottom of the wells. Applying an 
electrical current across the electrodes causes the generation of a luminescent signal by the 
chemical energy ligand-binding reactions. Quantitation of the signal converts the measurement to 
antibody concentration. This method has been applied to measurement of proteins and has the 
potential for greater sensitivity and faster results compared to the traditional ELISA method 
(Guglielmo-Viret, Attree, Blanco-Gros, & Thullier, 2005; Ma, Niezgoda, Blanton, Recuenco, & 
Rupprecht, 2012). 
Lateral flow immunoassays to detect and measure antibodies are useful for field work 
and in areas where a low tech screening method is required. By adapting the concepts of ELISA 
to an absorbent test strip, the testing process is simplified to progress across a straight line by 
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having the sample interacting with the assay reagents sequentially (see Figure 1.4 D.). A version 
of this method for detecting rabies virus antibody requires an initial step of mixing the serum 
sample with inactivated virus before adding the mixture to the absorbent material of the test strip. 
The mixture then flows across to encounter a labeled anti-rabies virus antibody which will bind 
to any unbound inactivated rabies virus. The mixture continues to flow toward two areas (lines) 
of the strip bound with detection antibodies; the first detection antibody is specific for the rabies 
virus, and the second detection antibody is specific for the labeled anti-rabies virus antibody. By 
using this design, if the mixture contains inactivated rabies virus bound with labeled anti-rabies 
virus antibody, there will a color development at the first strip, indicating the sample did not 
contain enough anti-rabies virus antibody to bind the inactivated rabies virus in the mixture. If 
the sample contains anti-rabies virus antibody, then the labeled antibody will pass the first strip 
and be bound by the labeled anti-rabies virus antibody causing a color development at the second 
strip. The results will be either positive (only second strip visible) or negative (first and second 
strip visible) for the presence of anti-rabies virus antibody in the test serum sample. The level of 
antibody to define positive or negative is set and defined by the design of the assay and can only 
be altered by concentration or dilution of the serum sample. Its simplicity and portability allows 
use by operators with a minimal amount of education and training. The lateral flow assay is 
useful for point-of-care situations where an initial rapid screening result would determine 
whether or not further action, such as additional testing or vaccination, was necessary.  
ELISA methods have several advantages including the fact that they are rapid, require 
little expertise, do not need high-level biohazard facilities to be performed and several steps of 
the procedure can be automated (i.e., serial dilution of the sera, addition of reagents and optical 
density reading). Additionally, software packages are available to calculate endpoint titers or 
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antibody concentration, thus allowing for objective reading and interpretation. The disadvantages 
of ELISA methods include the restrictive nature of the conjugated antibody or protein A that 
limits the isotype of immunoglobulin detected. The use of species-specific anti-IgG confines the 
utility of the assay to a certain species. Additionally, although the use of protein A increases test 
application to several species, it does not react with all forms of IgG3 and therefore will lead to 
an underestimation of the level of rabies virus-specific antibodies in serum containing higher 
proportions of IgG3 antibodies (Carpenter, 1997). The degree of non-specific binding detected 
by an ELISA will depend on the purity of the antigen preparation and the efficiency of the 
coating step because immunoglobulins will non-specifically adhere to glass, plastic, and also to 
contaminating material (i.e., mycoplasma) or cell culture components. Quantification of IgG 
antibodies that bind to rabies virus will not precisely demonstrate the level of protective virus 
neutralizing antibodies present in the sera. Therefore, the ELISA method is not appropriate for 
attempting to measure the amount of RVNA. Reporting of ELISA results in IU/ml is not 
reflective of this unit of measurement as defined by the WHO, where 1 International Unit of 
neutralizing activity is present per mg of protein. Therefore, the use of IU/ml to describe an 
antigen-binding assay for a rabies virus titer result is misleading. Since not all binding antibodies 
neutralize virus, whether for rabies virus or other pathogens, titers obtained from antigen-binding 
assays are not biologically identical to RVNA titers and therefore, ELISA-based test results 
should only be ordered, used and interpreted by informed health care providers, whether 
veterinary or human,  or researchers, for the optimal prevention of rabies. 
 Defining “adequate” or “minimum” response to rabies vaccination 1.7
It is well known that vaccination resulting in production of rabies virus neutralizing 
antibodies (RVNA) prevents rabies in persons who have been in contact with a rabid animal. 
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There is no specific RVNA level equivalent to protect against rabies virus infection and 
progression to the disease has ever been or is likely to be established due to the unethical nature 
of conducting efficacy studies in humans who have various levels of RVNA and to determine 
survival rates. Humans who have an increased risk of rabies exposure are vaccinated pre-
exposure to provide protection for unnoticed exposures and to reduce the vaccination schedule 
upon known exposure. This population should have periodic RVNA titer checks to evaluate the 
need for booster vaccinations. There are two major sources of guidelines in regard to an adequate 
response to rabies vaccination: the World Health Organization (WHO) Expert Committee on 
Rabies and the Advisory Committee on Immunization Practices (ACIP). Because the acceptable 
level given by these two guidelines are different and there is lack of understanding of how these 
levels were obtained and what they mean, there is confusion in the medical and veterinary fields 
about how to interpret rabies serology results in regard to booster vaccination decisions. Health 
professionals need a clear guideline to reference in making life-saving decisions about rabies 
treatment, for both pre- and post-exposure situations. The guideline instructions should clearly 
define the acceptable RVNA level in terms applicable to the recommended laboratory methods 
and clarify if there are situations where a different level may apply. 
Because rabies is preventable by vaccination which produces rabies virus neutralizing 
antibodies (other immune mediators may be at play but are not readily measured), use of 
methods to quantitate RVNA are preferred when testing for vaccine response in humans. 
Currently the most utilized method for this purpose is the RFFIT (and modified RFFIT methods). 
Not only should the method for this purpose be confirmed to measure neutralizing antibodies, 
but it should also be standardized to allow comparison to other laboratories and to established 
guidelines for human vaccination and vaccine manufacturer’s instructions. The method needs to 
38 
provide results that can be related to the guidelines in regards to units of measure and ability to 
detect the level stated. While no specific RVNA level has been identified as representing 
absolute protection under all circumstances and in all hosts against all rabies virus variant 
infections, RVNA levels attained by the majority of subjects in vaccine clinical trials formed the 
basis for the levels currently recognized as the minimal adequate response in vaccinated humans.  
Although the ACIP defines a method, it does not define the adequate level of RVNA in 
standardized terms. “Complete neutralization at a serum dilution of 1:5 in the RFFIT” can 
represent different titers and IU/mL values in laboratories which perform “modified” RFFIT 
assays. Besides standardizing the value reported for rabies serology, defining the specific 
parameters and standard reagents that comprise acceptable methods for RVNA measurement 
would aid in interpreting results for the determination of the need for booster vaccination.  
The ACIP states rabies serology should be performed by the RFFIT and both the OIE and 
WHO recommended methods are serum neutralization assays (FAVN and RFFIT), but other 
rabies serology methods are available, particularly ELISA methods, and may be inadvertently 
ordered. This may be especially true if samples from humans are collected and sent for “rabies” 
titer through a commercial human medical laboratory. Understanding the method and then 
interpretation of the result is essential for the optimal management of humans and animals. 
Indirect ELISA methods detect and measure the presence of rabies virus specific antibodies 
based on their binding ability; they do not measure the neutralizing ability of the antibodies (Irie 
& Kawai, 2002). The relationship between the level of binding antibodies and neutralizing 
antibodies cannot be predicted and is not linear. The validity of a method is unique to each 
laboratory and the parameters of a validation should be carefully considered. Method validation 
documents performance standards and includes identification and verification of the lower limit 
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of quantitation (LOQ). This is the lowest level that will produce accurate and precise results. 
Performance of a method within each laboratory that generates a rabies serology result and 
consideration of the rationale behind the two different definitions of adequate rabies vaccine 
response will need to be considered toward the development of clear language in regard to 
clinical management of persons or animals at-risk for exposure or following an exposure. 
 Conclusions 1.8
Rabies serological laboratories serve a critical function in rabies prevention programs. 
They are vital for providing reliable information required for human diagnoses, vaccine 
evaluations, animal surveillance and epidemiological studies and for routine testing of 
professionals working in the field of rabies. As outlined in the chapter, accurate rabies 
serological testing can be highly complex. The choice of the correct method for testing depends 
directly on what the intended purpose of the test results will be. Understanding the principle and 
limitations of the assay chosen and strict adherence to key components of testing will ensure 
appropriate results for decision-making.  
Guidelines for adequate vaccination should be readily understood by individuals-at-risk 
(whether human or animal) and health care providers, both veterinary and medical, who will use 
the recommendations for clinical management of individuals. The guidelines should clearly 
define the adequate response by test method; result format; and in consideration of method 
validation and method performance, especially the ability to differentiate a specific antibody 
response from a non-specific (or “false positive”) result. 
 Across the globe, there are different official regulatory standards and guidelines, both 
national and international for drugs and related product approvals. Each has a common goal to 
ensure the integrity of the laboratory data; protect human welfare; and provide safe and effective 
40 
products. These goals can only be met if all aspects of the testing and phase developments are 
held to the appropriate regulatory standard and monitored throughout the development process. 
The implementation of these standards must be from the beginning of the work at bench level to 
the end of the process which often continues during clinical use of products intended for the 
improvement or protection of human and animal health, including direct assessment of, and 
assessment of host responses to, rabies vaccines and sources of polyclonal and monoclonal 
products for the prevention of rabies. 
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Chapter 2 - Factors influencing the serological test results 
in rabies virus neutralizing antibody titers: 
The use of homologous vs. heterologous challenge virus strain 
 Abstract 2.1
The effect that the relatedness of the viral seed strain used to produce rabies vaccines and 
the strain of challenge virus used to measure rabies virus neutralizing antibodies after 
vaccination was evaluated. Serum samples from 173 subjects vaccinated with either purified 
Vero cell rabies vaccine (PVRV) produced from the Pitman-Moore (PM) seed strain of rabies 
virus or purified chick embryo cell rabies vaccine (PCECV) produced from the Flury low egg 
passage (Flury-LEP) seed strain of rabies virus were tested in parallel assays using a homologous 
and a heterologous testing system. In the homologous testing system, CVS-11 was used as the 
challenge virus in the assay to evaluate the humoral immune response in subjects vaccinated with 
PVRV and Flury-LEP was used for subjects vaccinated with PCECV. In the heterologous testing 
system, CVS-11 was used as the challenge virus in the assay to evaluate subjects vaccinated with 
PCECV and Flury-LEP was used for subjects vaccinated with PVRV. Although the difference in 
Glycoprotein (G) protein homology between the CVS-11 and Flury-LEP rabies virus strains has 
been reported to be only 5.8%, the use of a homologous testing system resulted in approximately 
30% higher titers for nearly two-thirds of the samples from both vaccine groups compared to a 
heterologous testing system. The evaluation of equivalence of the immune response after 
vaccination with the two different vaccines was dependent upon the type of testing system, 
homologous or heterologous, used to evaluate the level of rabies virus neutralizing antibodies. 
Equivalence between the vaccines was achieved when a homologous testing system was used but 
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not when a heterologous testing system was used. The results of this study indicate that the strain 
of virus used in the biological assays to measure the level of rabies virus neutralizing antibodies 
after vaccination could profoundly influence the evaluation of rabies vaccines.  
 Introduction 2.2
The immune response to rabies vaccination involves activation of rabies virus-specific B 
cells which differentiate into plasma cells producing antibody and memory B cells.  Although 
antibodies specific for the rabies virus glycoprotein (G) and nucleoprotein (N) proteins (as well 
as other rabies viral proteins) are produced after vaccination, published reports indicate that it is 
the antibodies specifically directed against antigenic components of the G protein that neutralize 
the rabies virus (Lafon, Edelman, Bouvet, Lafage, & Montchatre, 1990).  Rabies virus-specific 
CD4+ T cells, primarily induced by the rabies virus N protein, assist in B cell immunoglobulin 
class switching and immunoglobulin production. The effector CD4+ T cells are also 
differentiated into central and effector memory T cells.  Due to the lack of a well-established, 
practical method to measure the cellular immune response against rabies virus and because 
rabies virus neutralizing antibodies (RVNA) are critical for protection against rabies infection, 
the standard method for determining the immune response that has occurred after vaccination is 
to measure the level of RVNA in sera. The World Health Organization (WHO) recognizes two 
RVNA tests for the measurement of humoral immunity after rabies vaccination: the Rapid 
Fluorescent Focus Inhibition Test (RFFIT) and the Fluorescent Antibody Virus Neutralization 
Test (FAVN). Both assays utilize the Challenge Virus Standard (CVS-11) strain of rabies virus 
as the challenge virus to quantitate the neutralizing activity of RVNA produced in response to 
rabies vaccine (Smith, Yager, & Baer, 1973; Cliquet, Aubert, & Sagne, 1998).  Previous studies 
have demonstrated the significant influence that the strain of challenge virus used in testing has 
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on the measurement of vaccine potency (Blancou et al., 1989; Ferguson, Wachmann, Needy, & 
Fitzgerald, 1987).  Indeed, published studies indicate that higher vaccine potency values are 
achieved when a homologous challenge virus is used for potency testing as compared to when a 
heterologous challenge virus strain is used.  A similar effect has been demonstrated in the 
serological test results from serum samples assayed for the presence of specific antibody against 
different genotypes of lyssaviruses including rabies virus.  For example, higher RVNA titers 
were obtained against rabies virus (lyssavirus genotype 1) as opposed to lyssavirus genotypes 2-
7 when the source of the antibody is pooled sera from person vaccinated against rabies virus 
(lyssavirus genotype 1) (Smith, 2002).  Additionally, another study reported variations in RVNA 
titer values when two different CVS strains were used as the challenge virus (Smith, 1991).   
There are several cell culture rabies vaccines licensed for use throughout the world. Many 
of these vaccines are produced from different rabies virus seed strains including:  Pitman-Moore 
(PM) rabies virus strain used to produce human diploid cell rabies vaccine (HDCV), purified 
Vero cell rabies vaccine (PVRV) and purified duck embryo cell rabies vaccine (PDEV); Flury 
high egg passage (Flury-HEP) or Flury low egg passage (Flury-LEP) rabies virus strain used to 
produce two different types of purified chick embryo cell rabies vaccine (PCECV); and Kissling 
rabies virus strain of Challenge Virus Strain used to produce rabies vaccine adsorbed (RVA).  
The PM and Kissling rabies virus strains originated from the brain of a rabid cow in France in 
1882 and the Flury LEP strain originated from a human patient in the USA who died of rabies in 
1939. Investigation of the phylogenic trees of the G and N rabies virus proteins originating from 
different vaccine seed strains indicate a closer relationship exists between the PM and CVS 
strains of rabies virus than between the Flury LEP and the CVS strains (Figure 2.1).  Published 
reports also indicate areas of differences exist between the amino acid sequence of the G protein 
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of CVS and PM and the G protein of CVS and Flury LEP rabies virus strains (Figure 2.2).  It is 
important to note that there are no amino acid differences in the known, mapped antigenic sites 
(Tordo, 1996).  However, six of the eight known antigenic sites (epitopes) of the G protein are 
conformational and any amino acid changes in close proximity to these epitopes could 
potentially affect the folding of the protein (Tordo, 1996).  Additionally, the transmembrane 
region has been reported to affect folding of the ectodomain resulting in subtle conformational 
changes of the antigenic sites (Maillard & Gaudin, 2002).  The production of RVNA involves a 
process of fine tuning of specificity resulting in the selection of B cell clones with the highest 
avidity to a specific antigen.  The potential differences in the G protein antigenic sites of the 
original seed virus strains used in the production of rabies virus could result in the preferential 
production of antibodies with the highest affinity for antigenic sites resembling the vaccine seed 
virus strain. Thus, the strain of challenge virus used in an RVNA assay and the type of vaccine 
that a person was vaccinated with could profoundly influence the serological test results after 
vaccination. If this proved to be correct, RVNA assays using homologous testing systems 
(wherein the strain of challenge virus used in the testing assay is closely related to the seed virus 
used to produce the vaccine that a subject received) would report higher titer values than 
heterologous testing systems (wherein the strain of challenge virus used in the testing system is 
less closely related to the seed virus used to produce the vaccine that a subject received). The 
following study was conducted to determine the influence that the strain of rabies virus used as 
the challenge virus in a serological assay (homologous versus heterologous) and the strain of 
seed virus used in the production of the rabies vaccine that a subject received has on the 
quantitative evaluation of RVNA.  
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Figure 2.1 Phylogenic relationship of rabies virus strains (courtesy of Iris Stalkamp, Institut für 
Virologie, Giessen, Germany). 
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Figure 2.2 Amino acid alignment of the rabies glycoprotein from Flury, CVS and PM strains 
(courtesy of Iris Stalkamp, Institut für Virologie, Giessen, Germany).  There are fewer amino 
acid sequence changes from CVS to PM (filled arrows) than CVS to Flury (open arrows).  The 
changes are not in areas of the mapped antigenic sites of the rabies glycoprotein (shaded 
triangles).  The transmembrane sequence is indicated by the boxed area. 
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 Materials & Methods 2.3
 Challenge Virus   2.3.1
Two strains of rabies virus were evaluated as the challenge virus fin the RFFIT assays 
used to quantitate the amount of RVNA present in serum samples. The CVS-11 strain was 
obtained from the Centers for Disease Control and Prevention (Atlanta, Georgia).  Seed virus of 
the CVS-11 was grown on BHK cells to produce stock virus.  The Flury LEP strain was obtained 
from Chiron Corporation (Marburg, Germany), stock virus was grown in primary chicken 
fibroblasts. Stock virus preparations were titered to obtain a working dilution of 50 TCID50.   
 Serum samples   2.3.2
Serum samples used in the analyses were obtained from subjects that had received the 
same simulated post-exposure vaccination regimen with either PCECV (n=86) or PVRV (n=87). 
Subjects did not receive rabies immunoglobulin (RIG). Serum samples that were collected on 
day 14 and day 90 after initial vaccination were included in the study.  Serum samples were 
randomly placed into five testing groups (Groups 1 through 5). Each group contained from 60 to 
120 serum samples including samples from subjects vaccinated with PCECV as well as subjects 
vaccinated with PVRV. All serum samples were coded to ensure that testing was conducted 
blindly and unsorted by vaccine group. 
  Equilibration of working dilution of challenge virus 2.3.3
The working dilution of the challenge virus was equilibrated to 50 TCID50 for both the 
CVS-11 and the Flury LEP rabies virus strains. The titer of the challenge virus was calculated for 
each test set of serological samples in order to assure equivalence in testing criteria. For all test 
runs, the titer of the challenge virus was maintained within one standard deviation of the average 
calculation (41.1 TCID50) for virus titer throughout the entire evaluation.  
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  Serological testing  2.3.4
The RFFIT, using CVS-11 and Flury LEP as the challenge virus strains in parallel, was 
used to assay all serum samples, as previously described (Smith, 1996). Briefly, 100 µL of each 
serum sample, in duplicate, was diluted in serial five-fold dilutions and loaded into 8-well lab-tek 
chamber slides after which 100 µL of the challenge virus, at a concentration of 50 TCID50, was 
added. Slides were incubated at 37
o
C for 90 minutes after which 200µL of a suspension of 5 X 
10
5
 BHK cells was added to each well. Slides were placed in a 5% CO2 incubator at 370C for 24 
hours.  After incubation, the slides were washed and fixed in 80% cold acetone, dried and stained 
with FITC conjugated anti-rabies antibody (Chemicon, Temecula, CA). Twenty fields/well were 
examined under 160X magnification using a fluorescence microscope for the presence of rabies 
virus and RVNA titers were calculated using the Reed and Muench method. Reciprocal titers 
were used in the evaluation in order to eliminate the need to calculate international units using 
titer results obtained form an international rabies reference serum that originated form subjects 
only vaccinated with a rabies vaccine produced from a PM seed strain of rabies virus. 
  Statistical analyses: 2.3.5
After all serum samples were tested separately with both the CVS-11 and the Flury LEP 
rabies challenge virus strains, the identification of the two vaccination groups (PVRV and 
PCECV) was unblinded and the RVNA titers were statistically analyzed to determine the effect 
of serological testing by means of a homologous vs. heterologous test.  To determine whether 
any strain-dependent difference in neutralizing antibody was magnified at higher titers, the titer 
results (both day 14 and day 90) were sorted into response groups, the geometric mean titer 
(GMT) of the groups was calculated, and the GMT by challenge virus was compared. 
Additionally, to determine whether maturation of the antibody response amplified the differences 
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in GMT, the titer responses by day of serum drawn were sorted and the GMT of the groups was 
calculated  and compared by challenge virus.  
Table 2.1 Titer of Challenge Virus Standard (CVS-11) and Flury low egg 
passage (Flury-LEP), the two rabies virus strains used as the challenge 
viruses for each serological testing group 
Serological testing group Titer of CVS-11 Titer of Flury-LEP 
1 42.1 41.1 
2 40 41.2 
3 41 40 
4 41.4 42.3 
5 41.1 40.9 
Geometric  mean 41.1 41.1 
Virus titer is expressed in TCID50. 
 
 
Table 2.2 Rabies virus neutralization antibody (RVNA) values for Rapid Fluorescent Focus 
Inhibition Test (RFFIT) using a homologous challenge virus testing system and a heterologous 
challenge virus testing system. 
Vaccine 
administered 
RFFIT testing 
system 
Challenge virus 
GMT (Range) 
Day 14 Day 90 
PCECV Homologous 
Flury-LEP 
1855 
(320 to 6300) 
265 
(45 to 1500) 
Heterologous 
CVS-11 
1275 
(145 to 5400) 
192 
(45 to 1100) 
PVRV Homologous 
CVS-11 
2364 
(360 to 8500) 
284 
(45 to 9500) 
Heterologous 
Flury-LEP 
1448 
(70 to 8500) 
196 
(45 to 19700) 
Serum samples were obtained from subjects vaccinated with purified chick embryo cell 
rabies vaccine (PCECV) or purified Vero cell rabies vaccine (PVRV) and were assayed 
using CVS-11 and Flury-LEP as the challenge viruses in the RFFIT. 
 
 Results 2.4
The virus titer of CVS-11 and Flury LEP, used as the challenge virus in each of the five 
serological testing groups, remained consistently equivalent throughout the testing period (Table 
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2.1).  There was a similar wide range of RVNA titers obtained for each vaccination group, 
independent of whether CVS-11 or Flury-LEP was used as the challenge virus strain (Table 2.2). 
There were two outlier reciprocal titer values in the PVRV vaccination group, 9,500 and 19,700, 
exhibited by the same subject on days 14 and 90, respectively. The GMT for each group 
indicates higher RVNA titers are reported when a homologous challenge virus strain was used in 
the serological assay. The RVNA test results of individual serum samples indicated that there 
was a clear trend to report higher titers when a homologous testing system (CVS-11 used as the 
challenge virus in the RFFIT for testing sera from subject vaccinated with PVRV and Flury-LEP 
used as the challenge virus in the RFFIT for testing sera from subjects vaccinated with PCECV) 
rather than a heterologous testing system (Flury-LEP used as the challenge virus in the RFFIT 
for testing sera from subjects vaccinated with PVRV and CVS-22 used as the challenge virus in 
the RFFIT for testing sera from subjects vaccinated with PCECV) was used (Figure 2.3). 
 
Figure 2.3 Serum samples from day 90 after administration of purified chick embryo cell rabies 
vaccine (PCECV) or purified Vero cell rabies vaccine (PVRV) given in a post-exposure 
prophylaxis regimen were analyzed twice by RFFIT. In one assay CVS-11 was utilized as the 
challenge virus in the RFFIT and in the second RFFIT, Flury-LEP was utilized as the challenge 
virus. The rabies virus neutralization titer (RVNA) result obtained for each serum sample was 
plotted according to the challenge virus used in the RFFIT. The line of unity represents expected 
RFFIT values that would be equivalent regardless of whether CVS-11 or Flury-LEP rabies virus 
was used as the challenge virus for patients vaccinated with PCECV or PVRV. Similar results 
were seen with the day 14 results (data not shown). 
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The RVNA values in both vaccination groups included titers in the low, medium and 
high range, regardless of which challenge virus used in the assay. Low, medium, and high ranges 
were designated for this set of results to determine possible trends associated with the strength of 
the antibody response. Nearly two-thirds of the samples from each vaccine group reported higher 
titers when a homologous challenge virus strain was used for the RFFIT assay, 63% for PCECV 
and 65% for PVRV.  Approximately 30% of the serum samples tested in each vaccine group 
reported titers that were the same value or similar (within one standard deviation) regardless of 
whether they were assayed using a homologous or a heterologous challenge virus strain.  
The percent reduction of reported RVNA titers, when switching from a homologous 
testing system to a heterologous testing system was 23%, 47%, and 33% respectively for the low, 
medium, and high response groups in the PVRV vaccination group and 27%, 25%, and 40% in 
the PCECV vaccination group (Figure 2.4). Thus, there was no clear trend of higher or lower 
RVNA titers related to the type of testing system, and whether the serum tested belonged to the 
low, medium, or high response group. The overall reduction in RVNA titer values when 
switching from a homologous challenge virus assay to a heterologous challenge virus assay was 
33% in reported RVNA titer values for the PVRV vaccination group, and a 31% reduction in 
reported RVNA titer values for the PCECV vaccination group. 
On both day 14 (data not shown) and day 90 the GMTs were higher when a homologous 
challenge virus system was used for the PVRV and PCECV vaccination groups (Figure 2.5). 
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Figure 2.4 Depicted are the geometric mean titers (GMT) of serum samples analyzed by the 
Rapid Fluorescent Focus Inhibition Test (RFFIT) and separated into high, medium and low titer 
results. Serum samples were collected from subjects vaccinated with purified Vero cell rabies 
vaccine (PVRV) or purified chick embryo cell rabies vaccine (PCECV), and tested with RFFIT 
in either a homologous or heterologous testing system. A homologous testing system included 
sera from subjects vaccinated with PCECV and analyzed by RFFIT using the Flury-LEP as the 
challenge and sera from subjects vaccinated with PVRV and analyzed by RFFIT using the CVS-
11 as the challenge virus. A heterologous testing system included sera from subjects vaccinated 
with PCECV and analyzed by RFFIT using the CVS-11 challenge virus and sera from subjects 
vaccinated with PVRV and analyzed by RFFIT using the Flury-LEP as the challenge virus. 
 
 
Figure 2.5 Serum samples from day 90 after administration of purified chick embryo cell rabies 
vaccine (PCECV) or purified Vero cell rabies vaccine (PVRV) given in a post-exposure 
prophylaxis regimen were analyzed by the Rapid Fluorescent Focus Inhibition Test (RFFIT) for 
rabies virus neutralizing antibodies, using different challenge virus strains. Depicted are 
geometric means of reciprocal titers (GMT), error bars represent 90% confidence intervals. 
Geometric mean ratios (PCECV/PVRV) of the different challenge strain comparison groups 
were calculated (90% confidence intervals in parentheses), resulting in equivalent titers when 
using the homologous challenge strain Flury-LEP for PCECV and CVS-11 for PVRV. 
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 Discussion 2.5
 Neutralizing antibodies play a critical role in immune protection against rabies infection. 
Therefore, it is appropriate to utilize RVNA assays to measure the immune response after rabies 
vaccination rather than relying on antibody-binding assays, which do not measure the function of 
the antibodies produced. Indeed, currently the most accepted approach for measuring the 
immune response to rabies antigen is to measure the amount of RVNA in serum. In the United 
States, the Advisory Committee on Immunization Practices (ACIP) recommends that RVNA 
testing should be performed by virus neutralization assays; those persons at risk of contracting 
rabies should have their RVNA levels measured periodically; and a booster should be 
administered to persons at risk of contracting rabies when their RVNA titer falls below complete 
neutralization of a specific quantity of rabies at a 1:5 serum dilutions by the RFFIT (the World 
Health Organization recognizes this level to be 0.5 IU/mL) (Centers for Disease Control and 
Prevention, 1999; World Health Organization, 1992).  The evaluation of serological levels of 
RVNA is also appropriate for patients who may be immunosuppressed, or when a patient may 
have had a severe adverse reaction to the vaccine.  Finally, new rabies vaccines are evaluated, 
licensed and approved for use partly by assessing the level of RVNA produced after vaccination 
in human subjects enrolled in clinical trials. 
As mentioned earlier, the CVS-11 strain of rabies virus, generally used as the challenge 
virus in RFFIT assays that are used to measure RVNA, differs in how closely it is related to the 
PM and Flury strains of rabies viruses that are used in the production of human rabies vaccines 
(Figures 2.1 and 2.2). These differences are in some instances located in the areas that are in 
close enough proximity to the antigenic sites (and also in the transmembrane region) to 
potentially affect the conformation of the antigenic sites. It is possible that the differences 
59 
between the strains of seed virus used in the production of rabies vaccines are enough to cause 
slight conformational changes in the antigen-binding site of the antibodies that are induced after 
vaccination. These slight differences in the antigen-binding site could cause the antibody to have 
a higher affinity for a challenge virus used in an in vitro assay that more closely resembles the 
antigen that caused its production in the first place. The results of our study indicate that the 
degree of homology between the strain of challenge virus used in the RFFIT to measure the 
immune response after vaccination and the strain of seed virus used to produce the vaccine that 
subjects received profoundly affects the reported RVNA values.  The use of challenge virus 
strains with equivalent titers in RFFIT assays resulted in approximately 30% higher RNVA titers 
in two-thirds of the serum samples we analyzed when a homologous testing system was used.  In 
addition, the level of the RVNA titer (high, medium, or low) had no obvious or consistent effect 
on the percentage of titer difference reported between the testing systems.   
In most cases the choice of challenge virus strain used in a rabies virus neutralization 
assay would not play a critical role in the evaluation of RVNA titers; for example, periodic titer 
evaluations and the determination of an immune response after post-exposure prophylaxis where 
the exact titer level is less important than the actual detection of neutralizing antibody. In 
addition, the strain of rabies virus used in a rabies virus neutralization assay is unlikely to be a 
determining factor in the measurement of RVNA titers in persons whose pre- exposure series 
may be from one vaccine source and subsequent booster(s) from another source.  Similarly, 
persons who have had a rabies exposure will have an immune response to the rabies antigens in 
the exposure strain and to the vaccine strain confounding the mix of antibodies produced.  For all 
of the above mentioned reasons it would provide no benefit to measure the RVNA response by a 
separate rabies virus strains.  In contrast, the measurement of the humoral immune response after 
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rabies vaccination for the specific purpose of evaluating a new vaccine makes the choice of the 
challenge virus used in a rabies virus neutralizing assay extremely important.  When the RVNA 
levels against vaccines made from two different parent strains are compared using an assay that 
employs a particular challenge virus strain in the testing system, the combined effect of the 
quantity, functionality, and specificity of the respective antibody response is measured. As 
demonstrated by this study, if the challenge virus used in the assay is more closely related to one 
parent virus strain than to the other, the titer results obtained will be biased toward the 
homologous vaccine.  Most importantly, the evaluation methods used to confirm an absence of 
significant difference between the immune response produced by two vaccines involve statistical 
comparisons of the GMT by the geometric mean ratio (GMR).  The Food and Drug 
Administration (FDA) defines bioequivalence as “pharmaceutical equivalents whose rate and 
extent of absorption are not statistically different when administered to patients or subjects at the 
same molar dose under similar experimental conditions.”(Food and Drug Administration & 
Health and Human Services, 2004).  In comparing statistical evaluation of each vaccine, the 
confidence intervals (CI) of the GMR are examined.  When the lower limit of the 95% CI is 
greater than 50% and the interval includes 100%, “non-inferiority” is achieved.  To determine 
the stricter standard of “bio-equivalence”, 90% CI of the GMR must lie within 80%-125%.  If 
this bioequivalence test is applied for the day 90 results in our study, the GMTs obtained for 
PCECV are inferior to PVRV when serum samples from subjects vaccinated with PCECV are 
tested in a heterologous testing system using the CVS-11 strain of challenge virus.  Conversely, 
the GMTs obtained for PVRV are inferior to PCECV when serum samples from subjects 
vaccinated with PVRV are tested in a heterologous testing system using the Flury LEP strain of 
challenge virus (Figure 2.5).  However, when a homologous testing system is used to test the 
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serum samples for subjects in each vaccination group, not only are the two vaccines non-inferior, 
they are equivalent. 
 Conclusions 2.6
This report ascertains that the choice of challenge virus strain used in rabies virus 
neutralization assays to evaluate the production of RVNA titers after vaccination should be taken 
into consideration when the titer values will be used for the evaluation of new or existing 
vaccines. Clearly, if quantifying the immune response to vaccine is objective, then using a 
homologous rabies virus strain in the testing would most appropriately reflect this goal.  Finally, 
it is important to remember that modern cell culture vaccines are highly effective and cross-
protection between strains has been demonstrated (Briggs, 2002; Lodmell, Smith, Esposito, & 
Ewalt, 1995).  The use a heterologous or homologous testing system to evaluate the level of 
RVNA as a measure of complete ‘protection’ against rabies infection is incorrect. To date, the 
level of RVNA required to be ‘protective’ against infection in humans is not known for several 
reasons, the most important of which is that it is unethical to conduct challenge experiments in 
humans to determine the level of RVNA required for protection. On the other hand, the use of 
rabies virus neutralizing antibody testing systems to measure the immune response to specific 
rabies antigens and the response to rabies vaccines  should not only be accurate and precise, but 
also meaningful.  
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Chapter 3 - Rabies vaccine booster decision and rabies serology: 
how to interpret results 
 Abstract  3.1
For people at risk of rabies exposure, the protection afforded by pre-exposure rabies 
vaccination is a significant health assurance measure. Though rabies vaccines are among the 
safest and most successful vaccines made, the level of immunity induced can wane over time 
while the level of risk may not. Periodic rabies titer checks are recommended by the two main 
sources of rabies prevention guidelines, the Advisory Committee on Immunization Practices 
(ACIP) in the United States and the World Health Organization (WHO). While both guidelines 
provide very similar instructions, there are some differences, such as the level of RVNA, that 
represent evidence of seroconversion or adequate response. These different levels--complete 
neutralization at a 1:5 serum dilution and 0.5 IU/mL--in combination with different rabies 
serology methods in practice can lead to misinterpretation when decisions about rabies booster 
vaccinations are made. Given the importance of rabies vaccination in the prevention of rabies in 
at-risk individuals and in people undergoing post-exposure vaccinations, the language in the 
ACIP guidelines in regards to rabies serology results and testing should be updated to provide 
applicable booster vaccination guidance and understandable definition of adequate response as 
related to rabies serology. 
 Introduction 3.2
Immunization against rabies with the vaccine produced by Pasteur in 1885, and which 
remained unchanged until the advent of tissue culture vaccines, involved multiple vaccinations 
and was not without serious consequences (Steele, 1975). In contrast, modern tissue culture 
vaccines are safe and effective (Wunner & Briggs, 2010). The safety of the vaccine combined 
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with the knowledge of the protective effects of RVNA upon rabies exposure led to the practice of 
pre-exposure vaccination for people at frequent or continuous risk of exposure. Initially, it was 
suggested that this population receive a booster vaccination every two years to ensure ongoing 
‘protection’ by RVNA (Centers for Disease Control, 1976). RVNA was measured in the early 
days of rabies vaccine development by the mouse neutralization test (MNT), a cumbersome in 
vivo test. Over-vaccination concerns and the implementation of a rapid test (RFFIT) for RVNA 
influenced a change from periodic booster vaccination to boostering only when the RVNA level 
falls below a level representing adequate protection (Centers for Disease Control and Prevention, 
1980). 
Pre-exposure vaccination serves two functions: one, to protect the person in case of 
unnoticed rabies exposure; two, to eliminate the need for passive immunization and reduce the 
number of vaccinations in the event of a rabies exposure (Centers for Disease Control and 
Prevention, 2008; World Health Organization, 2012). The main protective effect of rabies 
vaccination is the production of rabies virus neutralizing antibodies (RVNA) (Hooper et al., 
1998).  Because the longevity of RVNA varies per person, guidelines recommend periodic 
checks to determine RVNA level and to administer a booster vaccination if the level is too low 
(Centers for Disease Control and Prevention, 2008; World Health Organization, 2012). However, 
the two main guidelines, the Advisory Committee on Immunization Practices (ACIP) and World 
Health Organization (WHO), while providing very similar instructions, differ when it comes to 
defining the adequate vaccination response which, along with other variables related to testing 
methods, can cause difficulty in deciding when a booster vaccination is needed. 
Rabies is universally feared due to the mortality rate--nearly 100%--and the ensuing 
horrific death. Though canine rabies, the primary source of human rabies cases globally, has 
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been eliminated in the United States in recent years, some areas remain rabies endemic due to 
wildlife rabies. Spillover from wildlife into domestic species and humans can occur (Leslie et al., 
2006). Those whose occupation and location put them at risk of rabies exposure know that rabies 
pre-exposure vaccination is a protective measure. Most know that measurement of rabies 
antibodies is required to show continued protection. What may not be clear is that different 
laboratory methods measure different aspects of the antibody response and that defining the 
seroconversion involves both the method and the specific guidelines followed. The Kansas State 
University Rabies Laboratory routinely tests serum samples from humans and animals for the 
level of RVNA. People at risk of rabies exposure undergo rabies pre-exposure vaccination and 
monitor their RVNA levels per the ACIP and WHO guidelines to determine if a booster 
vaccination is required based on the RVNA result obtained upon rabies titer check.  
The document globally referenced for defining adequate protection from rabies is the 
1992 Report WHO Expert Committee on Rabies (World Health Organization, 1992). The 
applicable section concerns persons who have undergone pre-exposure rabies vaccination. It 
simply states if a person’s RVNA titer is below 0.5 IU/mL, a booster vaccination is 
recommended. The ACIP first issued recommendations for RVNA titer testing in 1980 (Centers 
for Disease Control and Prevention, 1980); mentioning “a titer < 1:16” is considered proof of 
RVNA presence. In subsequent ACIP updates, this level has been described in various ways (see 
Table 3.1). The current ACIP version (2008) states the level as “complete neutralization at a 1:5 
dilution of serum in the RFFIT.” Both the 0.5 IU/mL and the complete neutralization at a 1:5 
serum dilution levels are referenced in the rabies vaccine instructions of the two vaccines in use 
in the United States--RabAvert and IMOVAX.  Numerous publications have mentioned the 
levels together and if not clearly stated, it can easily be interpreted or inferred that these levels 
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are the same--one in IU/mL format and one in titer format (Dreesen, 1999). This is not the case. 
To understand the two different levels, a description of the origins of these levels is helpful. 
 
Table 3.1 Guidelines for humans pre-exposure vaccinated and at risk of rabies exposure 
 
Agency/Year Booster vaccination recommended if level is below: Method of Testing: 
WHO 
1992 
 
 
0.5 IU/mL 
 
 
MNT or RFFIT; ELISA only with caution 
2005 0.5 IU/mL RFFIT or FAVN; ELISA if RFFIT not 
available 
2013 0.5 IU/mL RFFIT or FAVN; ELISA 
 
ACIP 
1976 None, boosters recommended every 2 years None stated 
1980 1:16 titer or booster every 2 years RFFIT 
1984 1:5 titer per CDC; 0.5 IU/mL per WHO RFFIT 
1991 1:5 titer 
a 
RFFIT 
1999 Complete neutralization at a 1:5 serum dilution 
b 
RFFIT 
2008 Complete neutralization at a 1:5 serum dilution
 c 
RFFIT 
a 
Recommended response 2-4 weeks after either pre- or post-exposure vaccination is complete neutralization at a 
1:25 serum dilution which is equivalent to the WHO level of 0.5 IU/mL 
b 
Recommended response 1-2 weeks after post-exposure vaccination is complete neutralization at a 1:5 serum 
dilution 
c 
RVNA titer most properly reported according to a standard as IU/mL 
 
The level of 0.5 IU/mL was recommended at the Joint WHO/IABS Symposium on the 
Standardization of Rabies Vaccines for Human Use Produced in Tissue Culture held in Marburg, 
West Germany in November 1977 (Bogel, 1978).  After the results of several international 
human rabies vaccine trials were presented, recommendations were given by specific Working 
Groups. According to Dr. Alexander Wandeler, a member of the 1992 Expert Committee on 
Rabies and a participant in the 1977 Joint WHO/IABS Symposium on Rabies Vaccines, the 
suggestion that low levels of virus inhibiting activity in sera may not be due to the presence of 
specific antibody came from the observation that virus inhibition was found in a fair proportion 
of sera of patients before they received any vaccination. Most of the nonspecific inhibition was 
reported in sera at dilutions of 1:5 or lower; a few results were higher (Kuwert et al., 1978; 
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Wandeler, 2014). The resulting assumption was that a serum should show virus inhibiting 
activity at dilutions of 1:10 and higher in order to give some confidence of the presence of 
specific antibody. To be on the safe side, virus neutralization at a 1:20 dilution as specificity 
threshold was suggested. The representative of IABS (F.T.Perkins) insisted that international 
units (IUs), not titers or serum dilutions be used to define this specificity threshold. Based on a 
variety of opinions Symposiums attendees agreed that a titer of 1:20 approximated 0.5 IU/mL 
(Wandeler, 2014). The Working Group for vaccine potency requirements of reduced 
immunization schedules and pre-exposure vaccination stated: 
“The group suggests that the serum be tested four weeks after the 
last inoculation and at that time a minimum value of 0.5 IU per ml 
be attained to demonstrate seroconversion.”((Bogel, 1978), p.270) 
Based on the subsequent reports of rabies antibody levels attained after pre- or post-
exposure vaccination series, the level of 0.5 IU/mL was globally accepted as proof of 
seroconversion (Smith, 2000). Similarly, the designated level in the ACIP was also based on 
RFFIT results from human vaccine trials in the 1970’s and the observation that non-specific 
inhibition (false positive) reactions were never seen at serum dilutions 1:25 or greater in the 
RFFIT (Smith, 2000). This led to the conclusion that if a specific RVNA titer result was detected 
(above complete neutralization at a 1:5 serum dilution), then seroconversion had been achieved. 
The level described in the ACIP is approximately 0.1 IU/mL in the RFFIT as originally 
described (Moore & Hanlon, 2010). Both levels are referenced in the manufacturer’s inserts for 
both current available rabies vaccines in the United States (IMOVAX and RabAvert) as an 
adequate or protective level of vaccine response (package insert, 2014; package insert, 2006). 
It should be noted that in none of these documents is it stated that a vaccinated human 
with an antibody titer of 0.5 IU/mL is protected against rabies virus infection. Therefore, both 
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levels, 0.5 IU/mL and 0.1 IU/mL, though five-fold different, are based on the same rationale--
specific detection of RVNA. The difference is the degree of confidence that the designated level 
can be assured to be a true measurement and not a “false positive.” The WHO does not define 
the assay to be used for antibody measurement, but in rationale recognizes the differences in 
testing methods and laboratory capabilities. The variance in rabies serology results was described 
in early publications on methods; wide differences in RVNA levels were obtained by MNT and 
RFFIT and by different laboratories (Bogel, 1978; Fitzgerald, Gallagher, Hunter, Spivey, & 
Seligmann, Jr., 1978).  The ACIP states that rabies serology should be performed by the RFFIT, 
thereby designating a single approved method. Neither the WHO or ACIP addresses the issue of 
whether the assay used has been validated to human clinical standards (CLIA, ICH, etc.) in the 
laboratory producing the results. Though the ACIP defines a method, it does not define the 
adequate level of RVNA in standardized terms. “Complete neutralization at a serum dilution of 
1:5 in the RFFIT” can represent different titers and IU/ml values in laboratories which perform 
“modified” RFFIT assays. The ACIP states rabies serology should be performed by the RFFIT, 
but other rabies serology methods are available to the public, particularly ELISA methods. 
Indirect ELISA methods detect and measure the presence of rabies specific antibodies based on 
their binding ability; they do not measure the neutralizing ability of the antibodies (Irie & Kawai, 
2002). The immune response to rabies vaccination involves antibody production that is 
polyclonal. Each individual production includes clonal antibodies that vary in affinity, avidity, 
and ability to neutralize the rabies virus. Therefore, the relationship between the level of binding 
antibodies and neutralizing antibodies is not constant; in one person, the ELISA result will be 
higher than the RFFIT result and in another person, the opposite can be true. Applying the 
“adequate” RVNA levels as described by WHO and ACIP to ELISA results may not be 
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advisable. A laboratory’s method validation should also be considered. Validation of a method 
verifies performance standards and includes identification and verification of the lower limit of 
quantitation (LLOQ) (FDA, 2001). This is the lowest level that will produce accurate and precise 
results. The LLOQ is the level that, by implication based on the history stated above, both WHO 
and ACIP recognize as showing adequate response to rabies vaccination. Examination of the 
method/laboratory used to produce a rabies serology result and the rationale behind the two 
definitions of adequate rabies vaccine response can aid in developing clear language for 
guidelines in rabies vaccination.  
 In May of 2010, the Rapid Fluorescent Focus Inhibition Test (RFFIT) results reported by 
the KSU Rabies Laboratory underwent a formatting change (from titer to IU/mL) in response to 
the ACIP recommendations. At the same time, instead of only referencing ACIP guidelines, the 
WHO recommendations were also included in the rabies serology report. By including the WHO 
recommendations, the interpretation of results more closely aligned with the vaccine 
manufacturers’ package inserts. In addition, areas outside the U.S. follow the WHO 
recommendations exclusively.  These changes highlighted the difference between the two 
guidelines. This difference is not new, but the existence of different levels may not have been 
commonly known. The ACIP recommends the use of the Rapid Fluorescent Focus Inhibition 
Test (RFFIT) because other methods [i.e., Enzyme-linked Immunosorbent Assay (ELISA), 
Lateral Flow] do not measure RVNA specifically and therefore cannot be correlated to the 
RFFIT. Because applying the WHO level will result in more vaccinated individuals falling 
within the “need for booster” group and ELISA methods may produce results not correlated with 
the guidelines levels, these important components relied on for vaccination decisions require 
clarification. Possibly related to the decision to reference both the ACIP and WHO rabies 
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vaccination guidelines on the laboratory reports, several veterinary schools reported an increase 
in numbers of students who require rabies booster vaccination. 
The KSU Rabies Laboratory performs the RFFIT test as recommended by both the WHO 
and ACIP for measuring human RVNA levels for booster vaccination decisions. Because there 
were concerns about the number of veterinary students requiring booster vaccination in recent 
years subsequent to the referencing both ACIP and WHO guidelines on the rabies serology 
reports, a retrospective study of rabies serology result from a subset of Veterinary Schools who 
have submitted samples for rabies titer check in the years 2005 to 2014 was performed. The 
objective was to determine whether a trend or change in the percentage of veterinary students 
requiring rabies vaccine booster exists over the years examined and to identify any differences 
between the schools. 
 Material & Methods 3.3
  Rabies serology 3.3.1
The study was performed under the Kansas State University IRB protocol 7062. The 
RFFIT, using CVS-11 as the challenge virus strain, was used to assay all serum samples, as 
previously described (Velleca & Forrester, 1981). The RFFIT assay has been validated for the 
purpose of measuring antibody response to rabies vaccination in the KSU Rabies Laboratory. 
Using the laboratory information management system (LIMS), RFFIT results were collated from 
the veterinary student serum samples submitted from six Veterinary School between the years 
2005 to 2014. Four of the schools had student sample submissions for each of those years; one 
school had sample submissions for all years except 2005 and 2008; and the remaining school had 
sample submissions from 2005 to 2011. The average number of samples submitted per school 
per year ranged from 114 to 201 for the years 2005 to 2014. Results were sorted into groups per 
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RVNA level as reported (< 0.1 IU/mL, >/= 0.1 IU/mL, or >/= 0.5 IU/mL) for each school per 
year. Percent of samples in each group was calculated per school and per year. Additionally, the 
results were grouped by titer decision level (using ACIP level of < 0.1 IU/mL and WHO level of 
<0.5 IU/mL as the levels to determine need for booster) and percentages calculated per school 
and per year. 
 Statistical analysis 3.3.2
Using the statistical software Analyze-it (Leeds, United Kingdom), percentages in each 
group were analyzed by ANOVA for difference between years and between schools; if 
differences were found, Bonferroni pairwise comparison was performed. 
 
Figure 3.1 Percentages of student rabies titers >/= 0.5 IU/mL (solid line), >/= 0.1 and < 0.5 
IU/mL (dashed line) and < 0.1 IU/mL (dotted line) for all veterinary schools combined for the 
years 2005 to 2014. 
 
 Results 3.4
There has not been a significant change in the percent of individuals who fall below 
published levels of minimum response to vaccination per this retrospective study of rabies 
serology results from six veterinary schools who annually submit veterinary student serum 
samples to the KSU Rabies Laboratory for rabies titer checks for the years 2005 to 2014 (see 
Figure 3.1). Leaving out the outlier values for one school (D) from 2007, the percentages (0-8% 
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for the ACIP level and 6-31% for the WHO level) are similar to previously reported for pre- 
exposure vaccinated individuals; 2-7% of vaccinated patients fail to continue to have antibody 
levels at complete neutralization at a 1:5 serum dilution after 2 years (Centers for Disease 
Control and Prevention, 2008), and 10-30% of persons having RVNA levels below 0.5 IU/mL 
one year after pre-exposure vaccination (Rodrigues et al., 1987; Strady et al., 1998; Banga, Guss, 
Banga, & Rosenman, 2014).  No obvious trend upwards or downwards in the percentage of 
students falling into each response group was noted. To illustrate the difference in percentages of 
students who require a booster vaccination based on their RFFIT results compared against the 
ACIP versus the WHO level, the percentages were graphed per year (see Figure 3.2). Table 3.2 
lists the mean percentages and range of students requiring vaccine booster, per year. No 
statistically significant difference between schools for percentages by ACIP or WHO level; or 
between years by ACIP level, but there was a statistically significant difference between years by 
WHO level (p<0.0005). Bonferroni pairwise comparison determined significant differences 
between the percentages of student requiring vaccine booster per the WHO level in the 
comparisons: 2011-2006, 2011-2008, 2011-2009, and 2011-2013. An evaluation of RFFIT 
results from student and employee groups from school A demonstrated that the percentages of 
persons requiring vaccine booster by either ACIP or WHO level did not peak or dip in the same 
years, data not shown. 
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Table 3.2 Average percent (and percent range) of students requiring rabies vaccine booster per 
the WHO or ACIP RVNA level guideline for the years 2005 to 2014 
Year ACIP WHO
 a 
2005 
3            
(0 to 6) 
16            
(15 to 23) 
2006 
3            
(0 to 8) 
12            
(9 to 17) 
2007 
6            
(1 to 13) 
22            
(10 to 44) 
2008 
2            
(1 to 3) 
12            
(6 to 15) 
2009 
3            
(1 to 4) 
14            
(10 to 19) 
2010 
4            
(1 to 6) 
20            
(10 to 25) 
2011 
5            
(2 to 8) 
26 
b
         
(21 to 31) 
2012 
2            
(0 to 4) 
18            
(11 to 22) 
2013 
2            
(1 to 3) 
11            
(7 to 14) 
2014 
2            
(1 to 3) 
19            
(13 to 24) 
a
 A statistically significant difference in the percent of students requiring rabies booster vaccine per the WHO level 
was determined between the years evaluated by ANOVA (p=0.0005). 
b 
A Bonferroni pairwise comparison determined a significant difference between the years 2011 vs. 2006, 2011 vs. 
2008, 2011 vs. 2009, and 2011 vs. 2013. 
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Figure 3.2 Percentages of students requiring rabies booster vaccination per the WHO guideline 
(RVNA <0.5 IU/mL) in panel A or per the ACIP guideline (RVNA <0.1 IU/mL) in panel B for 
the yars 2005 to 2014 by school: A (solid black line), B (dotted black line), C (dashed black 
line), D (solid grey line), E (dotted grey line) and F (dashed grey line). The expected percentages 
per previous studies is marked with a bracket on the right of the graph in both panel A and panel 
B. 
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 Discussion 3.5
For obvious reasons, the RVNA levels assigned as adequate cannot be scientifically 
verified; therefore animal challenge studies provide information about the relationship between 
rabies serology results and survival from challenge. In a review article summarizing rabies 
challenge studies, valid cut-off values for RFFIT results in cats and dogs, of 0.1 and 0.2 IU/mL 
respectively, were identified (Aubert, 1992). The level determined by a prior study in dogs was 
similar, dogs with titers below 1:20 succumbing to rabies challenge and the statistically predicted 
risk of rabies death decreasing with rising titers up to 1:50 (Bunn & Ridpath, 1984). There have 
been very few rabies cases in humans who have had pre-exposure vaccination. Of the three 
published accounts, one patient was vaccinated with an experimental vaccine and did not have a 
detectable titer one year post-vaccination (Winkler, Fashinell, Leffingwell, Howard, & Conomy, 
1973), the second had a titer of 1:32 five months prior to the exposure (MMWR, 1977), and the 
third did not have a titer test after vaccination, but did not have a detectable titer at time of 
clinical onset (Bernard et al., 1985). In an investigation of the third case, 9 of 11 other persons 
vaccinated at the same time, with the same vaccine lot and same schedule as the patient were 
found to have no detectable rabies titer. 
The level of protection as defined by rabies antibody levels cannot be ascertained for 
humans. As with most vaccines, high and low responders as well as range of longevity of 
response are expected due to many factors, including individual polygenetic major 
histocompatibility complex (MHC) genetic make-up (Kuwert, Barsenbach, Werner, & Mardus, 
1981; Haralambieva et al., 2013). There has been no change in the recommendations of either 
WHO since 1992 or ACIP since 1999. There has been no change in the percentage of individuals 
maintaining an adequate response to rabies vaccination based on the result of this study in 
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comparison to historical data, but there continues to be a misunderstanding of the relationship 
between the two guidelines and between results of different rabies serology methods. 
Vaccine titer checks are used to assure the vaccinated person has continued humoral 
immune response to the vaccine, with recommendation to boost if there is low to no response. A 
detectable level should be sufficient for most persons at frequent risk of rabies exposure in the 
United States where rabies awareness and availability of rabies vaccination post-exposure is 
good and canine rabies is not endemic. A detectable level is the level validated (to human 
clinical standards) for the method in use and in the laboratory performing the testing. This level 
should be robust enough to account for the variability of human serum samples and of the 
method. The percentage of unvaccinated persons whose serum samples demonstrate non-specific 
inhibition of virus in the RFFIT at the 0.1 IU/mL is nearly double the percentage at the 0.2 
IU/mL level, indicating the lower the level set for proof of adequate response to vaccination the 
larger the number of “false positives” reported. The primary purpose of rabies titer checks is to 
determine a detectable response to vaccination, and the prevention of rabies is thought to rely on 
RVNA; it follows that a low probability of “false positives” should be the primary criteria for an 
assay used for rabies titer checks. Per RFFIT method validation and historical data at KSU 
Rabies Laboratory, 0.2 IU/mL is the level where there is high confidence of a specific, detectable 
rabies antibody response (Kostense et al., 2012). A factor to keep in mind for consideration of 
assigning a level for rabies booster decisions are the timing of the blood draw. The majority of 
the antibody response shortly after the vaccination series has begun will be IgM which may not 
provide much protection in interstitial areas of the body, therefore a high level detected in the 
early days of response may not be as “protective” as a lower level of IgG several weeks, months, 
and years after vaccination. The level of 0.5 IU/mL was determined to be the level expected 4 
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weeks post-vaccination using serum neutralization assays (MNT and RFFIT). For post-exposure 
vaccination response evaluation, considerations such as the rabies virus variant, severity and 
location of the bite exposure, and the immune system condition of the patient can influence 
clinical decisions of the required level. The patient’s physician(s) should make these decisions 
and consult with epidemiologists and public health professionals. 
 Conclusions 3.6
The extent of rabies antibody response to vaccination varies per individual, but within an 
expected range for both the immediate (early-high and late-low) and the longevity response. 
Besides defining rabies exposure, risk groups, and vaccination schedules and regimens; national 
and international guidelines and vaccine instructions need to unambiguously state the RVNA 
level that is considered to be an adequate response to vaccination, both for pre-and post-exposure 
situations. This level should be termed in a standard format (IU/mL) and with consideration of 
methods that are recommended and validated for this purpose. Given the importance of rabies 
vaccination in the prevention of rabies in at-risk individuals and in people undergoing post-
exposure vaccinations, the language in the guidelines in regards to rabies serology results and 
testing should be updated to provide applicable booster vaccination guidance and an 
understandable definition of adequate response. 
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Chapter 4 - Differences between rabies serology methods affect cut-
off values for determination of adequate vaccine response 
 Abstract 4.1
Vaccine equivalency, booster administration, and animal import decisions are based in 
part on the level of rabies virus neutralizing antibody (RVNA) in serum. The RVNA level 0.5 
IU/mL (International Unit per milliliter) is recognized by the World Health Organization to 
represent an adequate response to vaccination. This cut-off value was selected after expert 
review of serum neutralization testing (SN) of clinical trial samples. Other methods are currently 
or can be employed to measure rabies vaccine response. Commonly the same cut-off value, 0.5 
IU/mL, is applied to provide information on which medical decisions are made. Studies have 
shown that although enzyme-linked immunosorbent assay (ELISA) and SN results are 
correlated, exact comparison cannot be ensured.  
This study investigated whether use of the 0.5 IU/mL cut-off value can be 
interchangeably used between different methods to provide the same vaccine response 
interpretation. Serum from rabies vaccinated subjects grouped by vaccine and vaccination 
regimen type were collected on days 0, 14, 30, and 90. The serum samples were tested by both 
SN and ELISA methods. At each time-point, the percentage of subjects producing rabies virus 
neutralizing antibody (RVNA) or anti-rabies antibodies above an assigned cut-off  as well as the 
individual result values were compared between groups.  Using either the SN or the ELISA 
results to compare vaccine-type groups for all time-points produced similar vaccine equivalency 
conclusions, but the comparison of the vaccination-regimen groups produced different 
conclusions dependent on test method used. Overall, the greatest difference between test method 
results was from samples collected at day 14 and day 30.   
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Directly comparing SN to ELISA results of clinical trial samples and covering a time-
point range encompassing the development and maturation of the humoral immune response, 
provides information on the kinetics of the rabies antibody response as defined by test method. 
Because SN methods measure neutralizing function and ELISA methods the binding function of 
rabies antibodies, the results are not expected to be equal; thus the cut-off values should be 
independently determined, not extrapolated between different methods.  
 Introduction 4.2
There are several different laboratory methods for detection and measurement of the 
(Bogel, 1978) rabies antibodies, yet the 0.5 IU/mL level is the one globally recognized marker of 
adequate response to vaccination in humans (World Health Organization, 2012). Often forgotten 
are the circumstances surrounding the origin of this determination. The World Health 
Organization (WHO) Expert Committee on Rabies (from the 3rd/1957 through the 6th/1973 
reports) states that the vaccination response should be verified in the serum one month after 
vaccination by detection of RVNA, but no specific antibody level is specified. A Working Group 
convened during the 1978 Joint WHO/International Association of Biological Standardization 
(IABS) symposium defined a cut-off value after review of RVNA levels obtained from several 
clinical trial studies for the newly developed cell culture rabies vaccines. The conclusion was 
presented “that the serum be tested four weeks after the last inoculation and at that time a 
minimum value of 0.5 IU per ml be attained to demonstrate seroconversion”(Bogel, 1978). In the 
WHO Expert Committee on Rabies Report from 1984, the 0.5 IU/mL cut-off value is described 
as the level expected one month after vaccination; and that booster vaccinations are required 
until that level is reached (World Health Organization, 1984). The key points are that the 0.5 
IU/mL antibody level was determined based on results from serum neutralization methods 
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(Mouse Neutralization Test or MNT and Rapid Fluorescent Focus Inhibition Test or RFFIT), 
was for specific time point (one month after vaccination), and was for a specified purpose 
(demonstrate seroconversion). To extrapolate this value to other methods, time points, and 
purposes is not supported without further investigation. In addition, referring to the level as 
protective is a misinterpretation of the original intent. 
SN and ELISA rabies serology methods have been compared many times and the 
findings are similar: correlation is fair to good (Nicholson & Prestage, 1982; Welch, Anderson, 
& Litwin, 2009; Elmgren & Wandeler, 1996) (Grassi, Wandeler, & Peterhans, 1989; 
Esterhuysen, Prehaud, & Thomson, 1995; Cliquet et al., 2004; Feyssaguet et al., 2007). This is 
not surprising as both methods are quantitating, in different ways, the specific rabies antibody 
response to rabies vaccination. The reasons SN and ELISA results cannot be considered 
statistically comparable for all samples are: the methods measure different characteristics of 
rabies antibodies (neutralizing function for SN and binding function for ELISA); and the normal 
antibody response to rabies vaccination is polyclonal, producing immunoglobulins with various 
epitope specificities, affinities, Ig subclasses, and neutralizing abilities--a unique polyclonal 
response per individual (Moore & Hanlon, 2010). This means the relationship of binding 
antibody measurement to neutralizing function will be variable between individuals. Similar 
issues have been described for discordant estimates of seroprevalence to mumps and measles 
using SN and ELISA methods (Mancuso, Krauss, Audet, & Beeler, 2008; Latner et al., 2014). 
This study investigated whether 0.5 Equivalent Units per milliliter (EU/mL) or another 
logical cut-off level could be determined by evaluation of the response as measured by ELISA 
using clinical trials samples (over set time points), analogous to how the 0.5 IU/mL adequate 
response level was established for SN methods. 
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The objectives of this study were to characterize the kinetics of the rabies antibody 
response to vaccination as defined by an ELISA method that detects anti-rabies glycoprotein 
IgG; to evaluate the ELISA method “adequate response” level by comparing antibody 
measurement units (EU/mL for ELISA versus IU/mL for SN); and to determine the degree of 
agreement between ELISA results and SN results for evaluation of vaccines or vaccine regimens 
for individual and group response. 
 Materials & Methods 4.3
 Serum Samples 4.3.1
Serum samples were obtained from subjects in a rabies vaccine regimen clinical trial. 
Subjects were placed into three groups based on vaccine and regimen types: Group A and B 
received purified Vero cell rabies vaccine (PVRV) with either the pre-exposure regimen (Group 
A, n=63); or post-exposure regimen utilizing Modified Thai Red Cross Schedule (TRC) (Group 
B, n=63); or purified chick embryo cell vaccine (PCECV) using TRC Schedule (Group C, n=63). 
All vaccines were administered via the intradermal route. Subjects did not receive rabies immune 
globulin (RIG). Serum samples collected on day 0, day 14, day 28 or 30 (referred to as day 30 
elsewhere in the report), and day 90 after initial vaccination were included in the study. All 
serum samples were coded to ensure that testing was conducted blindly. The study was approved 
by Kansas State University Institutional Review Board, protocol 7012. 
 Serological testing 4.3.2
All serum samples were tested with both a SN and ELISA method. 
The SN method, the RFFIT, was performed as previously described (Velleca & Forrester, 
1981) and validated for use with human sera at the KSU Rabies Laboratory. The challenge virus 
strain used was CVS-11. RVNA titer values were standardized to IU/mL values by comparison 
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with the Standard Rabies Immune Globulin (SRIG) (WHO 1st international RIG/Lot R-3 
FDA/CBER). 
The indirect ELISA method, Bio-Rad Platelia Rabies Kit II ELISA (Marnes-la-Coquette, 
France) was performed using the Bio-Rad Evolis instrument per the manufacturer’s instructions. 
The kit contains strips of wells coated rabies glycoprotein (G protein) for use as the antigen. The 
secondary (detection) system is an enzyme conjugated Staphylococcus aureus protein 
A/substrate color reaction. The results were reported in EU/mL (anti-rabies glycoprotein level) 
calculated by comparison of the sample optical density reading against a standard curve of 
positive standards supplied in the kit. 
Samples producing results above the upper level of quantitation (ULOQ) per each 
method were pre-diluted and retested to obtain an endpoint result within the range of each assay. 
Both assays have been validated for the purpose of measuring antibody response to rabies 
vaccination in human sera in the Kansas State University Rabies Laboratory. 
 Statistical analysis 4.3.3
After serological testing was completed, the identification of the groups was unblinded 
and the IU/mL and EU/mL results were analyzed for comparison of the two methods by the basis 
of percentage of each group’s subjects achieving adequate vaccination levels at days 14, 30 and 
90. The average IU/mL and EU/mL of each group was calculated by day and the students t-test 
used to determine significant difference (p=0.05). The kappa test was used to determine 
agreement between the methods using different cut-off values to determine a logical, useful cut-
off value for the ELISA method. Additionally, statistical comparison of individual results, 
IU/mL versus EU/mL, by a paired t-test was performed, to determine if a consistent relationship 
between RFFIT and ELISA results could be established. 
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 Results 4.4
The anti-rabies glycoprotein levels (EU/mL) as measured by ELISA peaked at day 30 on 
average though there was a lesser peak at day 14 as compared to day 30 while the peak IU/mL 
values as measured by RFFIT was at day 14 (see Figure 4.1). The anti-rabies glycoprotein levels 
were consistently lower than the RVNA levels on day 14 and day 30 for all groups (to greater 
extent in groups B and C) and nearly equal to the RVNA levels at day 90. The range of IU/mL 
(RFFIT) and EU/mL (ELISA) were similarly wide in each group and at each day with the widest 
ranges occurring at days 14 and 30 (see Table 4.1). Subjects with the highest levels of response 
were identified by both methods; two subjects in Group B both had RFFIT and ELISA results of 
>/=200 IU/mL or EU/mL at day 14. 
 
Figure 4.1 Kinetics of rabies vaccine response as measured by RFFIT (RVNA IU/mL) in panel 
A and as measured by indirect ELISA (anti-rabies glycoprotein EU/mL) in panel B. 
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Table 4.1 Median and range of rabies antibodies per group per day and by test method. 
 
 
The relationship between RFFIT and ELISA results per individual as examined in all 
groups/subjects was variable and particularly affected by day of blood collection (see Figure 4.2 
A). At 14 days post-vaccination, the majority of subjects had RFFIT results more than 50% 
higher than their ELISA result. On day 30 the results were of a mixed relationship with some 
subjects having higher RFFIT than ELISA results, others with results within 50%, and a smaller 
portion of subjects with higher ELISA than RFFIT results. By day 90, the majority of subjects 
had ELISA and RFFIT results that were comparable within 50%; the next largest group having 
ELISA results than their RFFIT results; and the smallest group had higher RFFIT results than 
their ELISA results. When each vaccine group was examined separately the same trend was 
observed but differing proportions in each category (see Figure 4.2 B). For example, in Group A 
there are approximately equal numbers of subjects with RFFIT and ELISA results within 50% as 
there are subjects with higher RFFIT/lower ELISA result whereas for Group C, nearly all the 
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subjects have higher RFFIT than ELISA results. The higher the RVNA level reached by a group 
the more discrepant the results between the two methods were at day 14 and day 30.  
Figure 4.2 The relationship of RFFIT IU/mL to ELISA EU/mL at different time points from 
vaccination overall (panel A) and by group (panel B). The number of subjects with RFFIT 
IU/mL greater than their ELISA EU/mL is in light gray, the number of subjects with RFFIT 
IU/mL with 50% of their ELISA EU/mL values is in gray, and the number of subjects with 
RFFIT IU/mL less than their ELISA EU/mL is in black. 
Using 0.5 IU/mL for RFFIT and 0.5 EU/mL for ELISA as the cut-off values, the number 
of subjects achieving an adequate response (percentage of subjects with results equal to or above 
cut-off value at day 14) between groups leads to different conclusions by method (see Table 4.2). 
Using ELISA results, Group A’s response is inferior to Group B’s at (34% versus 100% 
achieving adequate response level, respectively); using RFFIT results the two groups are more 
similar in response with 76% Group A and 100% Group B subjects reaching the cut-off levels. 
However in the comparison of Group C to Group B, the groups appear to produce nearly the 
same percentages above the cut-off values by both test methods, 92% versus 100% by ELISA, 
and 100% versus 100% by RFFIT. The groups by day were analyzed using the student’s t-test to 
determine whether use of method would affect the assessment of group differences. The vaccine 
responses as measured by ELISA for Group A compared to Group B and for Group C compared 
to Group B are determined to be significantly different (p=0.05) at both day 14 and day 30, while 
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the response as measured by RFFIT determined only Group A compared to Group B at day 14 
were significantly different. 
 Table 4.2 The percentage of subjects with adequate response to rabies vaccination using 0.5 
IU/mL for RFFIT and 0.5 EU/mL for ELISA as the definition. Comparison of groups A and B 
represent comparison of vaccine regimen and groups C and B, vaccine type. 
 
Head to head RFFIT/ELISA comparison of individual results demonstrated a wider 
discrepancy at day 14 than at day 90 (see Figure 4.3). For example, graphing the Group C 
individual responses clearly shows the varying kinetics of RVNA and anti-rabies glycoprotein 
response by both time (days from vaccination) and magnitude (level) (see Figure 4.4) due in 
large part to the inability of the ELISA method to detect IgM (only IgG anti-rabies glycoprotein 
binding measured) while RFFIT detect neutralizing antibody of both IgG and IgM class. The 
variation of response by individual is demonstrated in Table 4.3 by selected subjects, some of the 
largest and smallest discrepant ELISA versus RFFIT results are noted. The best agreement 
between RFFIT and ELISA result values for individuals was found at day 90 (with the majority 
of values within 50%) and yet large variation in results (both in value and in which method 
produced higher values) from the two methods were present at all the time points. 
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Figure 4.3 Correlation of RFFIT IU/mL to ELISA EU/mL results at day 14 (panel A) and at day 
90 (panel B). Result values were log transformed and are displayed with the RFFIT results on the 
x-axis and the ELISA results on the y-axis. The regression line is the black dashed and the line of 
identity is the solid black. 
 
 
Figure 4.4 Individual results, RFFIT IU/mL in panel A and ELISA EU/mL in panel B, for 
subjects in group C. The results of one subject with very high ELISA (63.96 EU/mL) and 
moderately high RFFIT (32.0 IU/mL) results at day 14 were not plotted to allow illustration of 
the peak of the majority of subjects results. 
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Table 4.3 RFFIT and ELISA result comparison of selected group C subjects at day 14 and day 
90. Subjects with nearly equal RFFIT (IU/mL) and ELISA (EU/mL) results are highlighted in 
red. 
 
 Discussion 4.5
In a broad view, both SN and ELISA methods for rabies serology measure the presence 
of antibody through a specific antibody-antigen interaction. Although other components of the 
immune system are involved, protection from clinical rabies after infection relies heavily on the 
presence of RVNA (Hooper, 1998). Because SN rabies serological methods detect the 
neutralization activity of RVNAs in vitro, mimicking the protective action of these antibodies in 
vivo, they are the best methods to quantify the level of immunity after rabies vaccination and 
subsequently the need for booster administration. The technical performance of SN methods, 
such as the RFFIT, requiring high levels of biosafety facilities and expertise makes the use of 
these methods a difficult proposition in some areas of the world. Antigen binding assays such as 
indirect and competitive ELISA methods are rapid, simple, and do not require manipulation of 
live rabies virus which makes them a practical alternative to SN methods. Simply replacing the 
method used for rabies antibody measurement and using the same cut-off value for “positive” 
and “negative” for purposes of determination of adequate response to rabies vaccination is 
problematic due to the inherent differences in how and what the different type of methods 
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measure. SN methods measure neutralizing function without differentiation of the contribution of 
immunoglobulin classes (IgM, IgG, and IgA) present in the sera. The usefulness in vivo of high 
levels of IgM neutralization activity is not as critical for inhibition of rabies infection as IgG, due 
to the inability of IgM to reach the interstitial areas of tissue with high levels of virus (typically 
from saliva in the bite of a rabid animal). Conversely, ELISA methods measure the level rabies 
specific binding antibodies regardless of the antibodies ability to neutralize the virus, and, 
depending on the secondary (or detection) antibody, may only detect IgG or certain subclasses of 
IgG. In response rabies vaccination, the humoral immune response will be primarily IgM at early 
days developing to mostly IgG after antibody maturation and class switching at later days. In 
addition, the response is polyclonal with the proportion of neutralizing to non-neutralizing 
varying per individual genetics as a major factor. For the study presented here, the comparison of 
SN to ELISA only applies to the RFFIT method as performed at KSU Rabies Laboratory against 
an indirect ELISA with rabies G protein as the antigen and protein A as the secondary. Other 
indirect ELISA methods (using other proteins or whole virus and secondary antibodies) or 
competitive ELISAs may produce various correlation and agreement to SN methods. 
Modification of either basic method, SN or ELISA, would require method validation including 
assignment of cut-off value for the purpose of testing.  
The results of this study indicate there is no consistent relationship between the two 
measures of rabies antibody response to vaccination (SN/RFFIT and indirect ELISA/Bio-Rad 
kit) either in degree of agreement or in direction of response (one always higher than the other) 
for individual subjects. Even though there is a larger numerical difference between the values 
produced by the two assays at day 14 and day 30, there are still individuals with significantly 
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different responses at day 90 where the primary class of antibody is expected to be IgG, 
demonstrating that antibody class alone is not the sole source of difference in the measures.  
The agreement of the two methods results from all subjects at all time points tested was 
determined by the kappa test.  Using the 0.5 value for both methods gives an agreement value of 
94.0%, kappa statistic 0.56 for determination of adequate vaccine response (see Table 4.4). To 
attempt the establishment of a cut-off level that ensures all “positive” ELISA results include only 
those subjects with a RVNA level of 0.5 IU/mL or above for measures on day 14, 30, and day 
90, a level of 1.0 EU/mL was identified as meeting this criteria. Nonetheless using the 1.0 
EU/mL for the ELISA cut-off level and 0.5 IU/mL for RFFIT reduces the overall agreement of 
results to 81.2%, kappa statistic 0.32 and as a consequence 106 discrepant results, all of which 
are >/=0.5 IU/mL by RFFIT and <1.0 EU/mL by ELISA. Of these 106, 76% are from day 14 and 
30 and 40% are below 1.0 IU/mL by RFFIT. This conservative cut-off level is designed for no 
overestimation of the neutralizing antibody level by ELISA testing in this set of subjects, for 
both early and late measures of antibody response and allows the use of the ELISA method as a 
screening test. Used in this manner, the ELISA would identify adequately vaccinated individuals 
(individuals that would be expected to have RVNA equal to or above 0.5 IU/mL); and 
individuals with ELISA results below 1.0 EU/mL would require testing by RFFIT to identify 
those with levels at or above 0.5 IU/mL. Based on this study, an estimated retest rate would be 
18.8% for samples drawn between 14 and 90 days after vaccination. Alternatively, if a less 
conservative level of 0.25 EU/mL for ELISA is used for comparison of with the 0.5 IU/mL 
RFFIT level, an overall agreement of results is 96.1%, but it allows 16 discrepant ELISA 
“positive”/RFFIT “negative” findings, hence labeling those subjects with antibody responses as 
adequate based solely on antibody binding levels. Use of this cut-off value scheme allows an 
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improved agreement of the comparison of “percentage above cut-off level” between Groups A 
and B for the ELISA results, with Group A at 70% and Group B at 100% subjects above cut-off 
at day 14. If the lower limit of quantitation (LLOQ) for both methods are used as cut-off levels 
(0.2 IU/mL for RFFIT at KSU and 0.125 EU/mL for the Bio-Rad ELISA), the agreement of 
methods becomes 97.2% for this set of subjects at time points of days 14, 30, and 90. 
If each time point is considered independently for assignment of ELISA result cut-off for 
best agreement and kappa statistic with the 0.5 IU/mL cut-off for RFFIT results, at day 14 it was 
0.25 EU/mL, and at day 90 it was 0.5 EU/mL; whereas on day 30 the use of the LLOQ for both 
methods as the cut-off value resulted in the highest agreement and kappa statistic values (see 
Table 4.4). Comparing individual results by the t-test pairwise indicates that only at day 90 was 
there no significant difference between the measures by RFFIT and ELISA (see Figure 4.5).  
Table 4.4 Each of the subjects results were categorized as ‘positive’ (having a result at or above 
the assigned cut-off value for the method) or ‘negative’ (having a result below the assigned cut-
off value for the method) and the kappa test used to determine agreement between the RFFIT and 
ELISA methods for determination of adequate response per day and overall for different cut-off 
schemes..  
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Figure 4.5 Average result values, IU/mL for RFFIT (gray bars) and EU/mL for ELISA (black 
bars). Significant difference (p<0.05) between method results were noted at days 14 and 30 as 
well as overall (*). 
 Conclusions 4.6
Rabies vaccine response can be measured by both antigen-binding and serum 
neutralization methods, but these measures are not the same due to differences in what and how 
each test measures. It is not expected that RFFIT and ELISA results have a consistent 
relationship since RFFIT measures neutralizing function of the rabies specific antibodies (IgG 
and IgM), which is not proportional in a defined degree to the binding ability of the rabies 
specific IgG antibodies as detected by the Bio-Rad ELISA kit. Assigning the same cut-off level 
for both test methods will never result in agreement for all individuals. The relationship of 
RFFIT and ELISA results over various time points post vaccination, as illustrated in this study, 
demonstrates further that one cut-off is not appropriate, though good agreement can be achieved 
by assigning logical cut-offs considering time point of blood draw post-vaccination for groups of 
subjects if not on an individual basis. Evaluating the kinetics of the RVNA/anti-glycoprotein 
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response, combined with laboratory validation of the specific test method and consideration of 
the use of the results (vaccine efficacy, determination of booster, detection of vaccine bait-
uptake) is a logical approach for setting a useful cut-off for both RFFIT and ELISA methods. 
The importance of choosing the method ‘fit for purpose’ AND ensuring that the testing 
procedure is conducted appropriately with adequate quality assurance procedures in place cannot 
be overstated for a measure as important as the RVNA level—the most important immune 
component for the prevention of clinical rabies. 
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Chapter 5 - The Detection of Antibodies to Vaccine and Field Strains 
of Rabies Virus in Horses by a Multiplex Microsphere-Based Assay  
 Abstract 5.1
Rabies is a fatal neurological disease caused by a RNA virus in the family 
Rhabdoviridae.  Prevalence among horses in North America is steadily increasing. The majority 
of rabies viruses isolated from positive horses in Kansas are skunk strains; however several bat 
strains have also been identified. The hypothesis that horses vaccinated with laboratory adapted 
rabies strains have weak antibody titers to virus variants occurring in nature was investigated. A 
multiplex-bead-based indirect immunoassay was developed to screen sera obtained from 
vaccinated horses against rabies antigens isolated from seven rabies virus isolates. This multi-
analyte technology (xMap) was designed to quantify equine IgG binding to viral antigens 
derived from the seven different rabies virus strains simultaneously. Characterization of the 
dominant viral proteins in the antigen preparations was performed by silver stain of SDS-PAGE. 
Coupling of viral proteins G and N derived from three laboratory rabies strains to three sets of 
xMag beads was confirmed. The 7-plex set of rabies antigen coated xMap beads was tested 
against serum samples obtained from18 horses before and after rabies booster vaccination. The 
results indicate that all horses were able to increase their vaccine response after booster, but a 
variety of responses were recorded to rabies strains that differ from the vaccine strain.  
  Introduction 5.2
Rabies is a fatal neurological disease caused by a negative single-stranded RNA virus in 
the Rhabdoviridae family that is transmissible to all mammals.  Although the incidence in horses 
is low, the disease has public health significance because of the potential for human exposure to 
the saliva and infected tissues from wildlife and domestic animals. The numbers of exposed 
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horses are increasing steadily, 44 cases in horses and mules were reported nationally in a 
surveillance study in 2011, an 18.9% increase compared to 2010 (Blanton, Dyer, McBrayer, & 
Rupprecht, 2012).  Six rabies virus strains have been isolated from wildlife in Kansas, 2 skunk 
strains, one raccoon, and three bat strains. In Kansas and Nebraska, of the eleven positive horse 
cases sequenced in 2012, 9 were typed as south central skunk and 2 as north central skunk. In 
2011 of the 6 positive horse cases sequenced, 4 were south central skunk, 1 north central skunk 
and 1 raccoon. Six of the seven cases in 2010 were south central skunk and the remaining case 
was raccoon.   Although bat strains have been isolated in positive horse cases nationally, it 
occurs rarely and they were not isolated in horses from 2010 to 2012 in Kansas and Nebraska 
where three bat virus strains are present including Eptesicus fuscus (big brown bat), Lasiurus 
cinereus (hoary bat) and L. borealis (eastern red bat).  South central skunk is the main rabies 
strain from North-Central Nebraska to Texas (KSVDL, 2015; Centers for Disease Control and 
Prevention, 2011). Horses are commonly housed outdoors and are at an increased risk for 
exposure to rabid wildlife, especially with urbanization of wildlife habitats.  
Several lyssavirus genotypes exist and include the classical rabies virus (RABV) with 
worldwide distribution and others with more restricted distribution and reservoirs such as 
Australian Bat Lyssavirus (ABLV), European Bat Lyssavirus 1 and 2 (EBLV1, EBLV2), Lagos 
Bat, Mokola, and Duvenhage. The American Association of Equine Practitioners (AAEP) 
currently includes rabies as a core vaccine in all equids (http://www.aaep.org/rabies.htm).  There 
are three commercial vaccines approved and licensed by USDA for rabies prophylaxis in horses 
(EquiRab, Intervet [Merck]; ImRab, Merial; and Rabvac3, Boehringer Ingelheim).  Vaccine 
strains are lab adapted strains of various origins with many related to Pasteur’s isolation and 
culture of a dog strain taken from a rabid cow from Paris, 1882 (Pasteur, Pitman-Moore), but 
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also includes a dog strain from a rabid human from Georgia, 1939 (Flury LEP) and a rabid dog 
from Alabama, 1935 (ERA). The rabies strain primarily used in laboratory methods to measure 
the immune response to vaccination is the Challenge Virus Strain-11 (CVS-11), which shares the 
highest degree of homology with the Pitman-Moore (PM) strain. All the vaccine strains and 
CVS-11 have been passaged thousands of times in rabbit or mouse brain and/or cell culture 
adapting them to production (Tordo, 1996).  Vaccine strains have been proven to elicit cross-
protection of strains with genotype 1, reduced protection with genotypes 2-5, and no protection 
with genotype 6 and 7(Smith, 1991).  Glycoprotein (G) is an immunodominant protein, is less 
conserved between strains than the nucleoprotein (N) protein, and is responsible for the receptor 
binding that leads to infection. One of the two most immunogenic sites on the G protein (site III) 
is also the most critical site for determination of pathogenicity (Tordo, 1996; Benmansour et al., 
1991; Johnson, McElhinney, Smith, Lowings, & Fooks, 2002). Response to vaccination is 
expected, based on titer testing of monoclonal antibodies, to be affected by antigenic differences 
between viruses (Benmansour et al., 1991). Several reports document variable reactivity of 
monoclonal antibodies with different vaccine and wild type rabies strains (Horton et al., 2010; 
Marissen et al., 2005; Sloan et al., 2007).  
Current diagnostic methods to detect humoral immunity in horses and other domestic 
species consists of enzyme linked immunosorbent assays (ELISA) to detect anti-rabies 
glycoprotein binding antibodies  or rabies virus neutralizing antibody (RVNA) assays to detect 
antibody that neutralizes virus and prevents infection of cultured cells. The virus strains used in 
these assays as the antigen are lab-adapted strains vaccine strains (or closely related).  
Microsphere-based immunoassays provide a new methodology capable of detecting multiple 
analytes (50 -100) simultaneously in a 50 to 96-well format (Kellar, Mahmutovic, & 
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Bandyopadhyay, 2006; Vignali, 2000). This technology (Luminex and Magpix) is widely 
commercially available for human samples to measure cytokines, antibodies, tumor markers, 
hormones, and many other analytes.  The technology utilizes unique sets of magnetic 
microscopes internally dyed with different fluorescent intensities that have unique spectral 
properties separated by fluorescent emissions.  Proteins, oligonucleotides, lipids, 
polysaccharides, or small peptides can be absorbed or chemically coupled to the microspheres to 
capture analytes that are measured by a fluorochrome-conjugated detection system.  The power 
of the technology and advantage over traditional immunoassays (i.e. ELISA) is that the analytes 
can be multiplexed and analyzed in the same sample of smaller sample volume with more 
reproducibility and less preparation than traditional ELISA assays (Dasso, Lee, Bach, & Mage, 
2002). The automated systems (Luminex and Magpix) provide a high throughput platform and 
recently have fully customizable bead sets for development.  In veterinary research, multiplex 
assays are beginning to be developed and implemented. Multiplex microsphere-based assays 
have been tested and validated to measure cytokines in horses and cats (Wagner & Freer, 2009; 
Wood, O'Halloran, & Vandewoude, 2011). Similar multiplex systems have been used to screen 
antibodies to viruses in pigs and to quantitate immunoglobulins in human sera (Dasso et al., 
2002; Lin, Wang, Murtaugh, & Ramamoorthy, 2011). It is our working hypothesis that horses 
vaccinated with the commercial rabies vaccine strain (PV) have weak antibody titers 
(concentration) to other virus variants that occur in nature.   Our objective is to determine the 
antibody response using a novel multiplex immunoassay in vaccinated horses to rabies virus 
variants including north central skunk, south central skunk, raccoon, and bat strains.  The results 
from the multiplex assay will be compared with traditional ELISA and neutralizing antibody 
assays. The findings from this study will have important implications in the current vaccine 
105 
practices, particularly if the vaccine strain does not invoke strong antibody responses to 
terrestrial rabies virus strains.  
To accomplish this objective, a multiplex-microsphere based assay was developed to 
quantify immunoglobulin G specific to the various rabies strains in horses vaccinated against 
rabies. The multiplex microsphere-based assay uses magnetic beads (up to 50 sets) that have a 
unique spectral profile. Through a chemical reaction vaccine proteins can be attached to each set.  
Protein-coated beads are then incubated with patient serum to allow for antibody binding.  A 
fluorescent strept-avidin detection conjugate is added; and a biotinylated secondary species 
specific (equine) antibody is used to complete the reaction.  The goals were to determine the 
antibody response in horses before and after vaccination, and to determine how well the rabies 
vaccine booster stimulates a humoral immune response to the vaccine strain and the terrestrial 
and bat rabies virus variants.  The 7-plex assay was used to compare pre- and post-vaccinated 
antibody concentrations. Antibody concentrations were compared to a single-plex ELISA and 
RVNA assay.   
 Materials & Methods 5.3
 Horse serum samples 5.3.1
 Ten horses from the Kansas State University herds and eight privately owned horses were 
enrolled in the study. Thirteen of the 18 horses had a history of prior rabies vaccination; the 
remainder had unknown rabies vaccine history. All horses were rabies vaccinated (Equirab, 
Merck) at time of enrollment. Blood samples were drawn on the day of rabies vaccination and 
again 14 days after. Blood samples were allowed to clot and centrifuged to obtain the serum 
samples. The serum samples were aliquoted in 2 mL volumes into freezer vials and stored at -
20
o
C until tested. 
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 Antigens 5.3.2
 The rabies viruses of the laboratory adapted strains (Challenge Virus Strain-11 [CVS-11], 
Flury-Low Egg Passage [Flury-LEP], and Evelyn-Rokitnicki-Abelseth [ERA]) were propagated 
in BHK-21 cells (WHO Laboratory Techniques in Rabies, 1996). The rabies viruses of the wild 
type strains (Eastern Pipistrelle, Tadarida, South Central Skunk and North Central Skunk) were 
adapted to MNA cell culture by initial inoculation of the cells with rabies-infected brain tissue 
taken from confirmed rabies positive animals by the Direct Fluorescent Antibody (DFA) test. 
The rabies virus in the brain tissues was genotyped by PCR/sequencing.  The infected cells were 
passaged until an adequate viral titer was obtained in the supernatant (between passage 6 and 9) 
to produce enough virus for the bead assay. Identity of the cell passaged viruses was verified by 
N and G sequencing. The harvested supernatants were centrifuged for 30 minutes at 5000 g to 
remove cellular debris and filtered through a 0.22 μm PES filter. The virus stocks were 
inactivated by mixture with β propiolactone (Sigma Chemical Company, St. Louis, MO) at a 
ratio of 1:4000 and incubated at 37C for 2 hours, shaking very 10-15 minutes. Complete 
inactivation was determined by serial passage of MNA or BHK cells mixed with 0.5 mL of the 
inactivated virus suspension and microscopic examination on each day of passage for virus 
infected cells using fluorescent conjugated anti-rabies antibodies. No virus was detected in the 
cultured cells. The inactivated viruses were concentrated (approximately 100X) with PEG10 
(PEG Virus Precipitation Kit, Abcam, Cambridge, MA). Each viral suspension was measured for 
protein (Pierce
TM
 BCA Protein Assay Kit, Thermo Fisher Scientific, Waltham, MA). The 
presence of rabies glycoprotein (G) in the virus preparations was verified by a silver stain of a 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. 
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 Coupling of rabies virus antigens and anti-IgG to beads 5.3.3
 Coupling of the antigen to the microspheres was achieved through a generic two-step 
carbodiimide coupling with sulfo-N-hydroxysulfosuccinimide (NHS) and 1-ethyl-3-[3-
dimethylaminopropyl] carbodiimide hydrochloride (EDC) (xMap kit, Luminex) according to the 
manufacturer’s instructions. Rabies whole virus was used as the antigen, produced as described 
above; 5 μg of each virus preparation was covalently coupled to 1.0 X 106 carboxylated 
paramagnetic microspheres (beads) (MagPlex microspheres, Luminex, Austin, Texas). 
Confirmation of the binding was determined by testing the coupled beads with mouse anti-rabies 
glycoprotein, (clone 0.N.541, 1:500 in PBS-1%Tween, Abcam, Cambridge, MA) and mouse 
anti-rabies nucleoprotein (clone C18-62-143-2, 1:500 in PBS-1% Tween, Light 
Diagnostics/Millipore, Darmstadt, Germany), and detected with R-PE-goat anti-mouse IgG 
(H+L) 2 μg/mL (Columbia Biosciences, Frederick Maryland) 
http://stores.columbiabiosciences.com/goat-anti-mouse-h-l-surelight-r-pe /. 
 Bead-based serology 5.3.4
 The assay was performed on a MAGPIX instrument (Luminex). Pilot experiments were 
performed to determine an optimal serum dilution and detection system concentrations for the 
measurement of equine antibody specific for the rabies virus strains. For each assay an equal 
volume (calculated volume dependent upon the number of tests to be performed so that there was 
at least 100 beads for each set) beads with a specific rabies virus strain were aliquoted to each 
well. Each test serum was serially diluted (1:125, 1:500, 1:2000, and 1:8000). For the assay, 50 
μL of each serum dilution was combined with 50 μL of the bead mix (2.5 X 106 beads/ mL) in 
wells of a 96 well reaction plate, incubated overnight in the dark at 4 º C on a shaker (200 rpm). 
After incubation, the contents of the well were washed with PBS-1% Tween twice and 
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resuspended in 50 μL PBS-1% Tween with aid of a magnetic plate separator per the kit 
instructions. Then 50 μL of the detection antibody, biotinylated goat anti-equine IgG (heavy and 
light chain) (Jackson ImmunoResearch) at a 2 μg/mL concentration was added to each well, 
incubated for 60 minutes at room temperature on a shaker followed by a wash as described 
above. Phycoerythrin-strepavidin (50 μL) (BioLegend, 4 μg/mL, in PBS) was added to each 
well, the plate was covered and incubated for one hour on a plate rotator (250 rpm) at room. For 
each sample 50-75 μL was analyzed on the Luminex MagPix instrument (xPonent, Luminex) to 
obtain the mean fluorescence intensity. The optimal serum dilution was determined to be 1:2000. 
 ELISA assay 5.3.5
The serum samples were analyzed with the Bio-Rad Rabies Platelia Kit II (Bio-Rad, 
Marnes-la-Coquette, France) an indirect ELISA method. The Bio-Rad Evolis instrument was 
utilized for the test performance per the manufacturer’s instructions. The kit contains strips of 
wells coated with rabies glycoprotein (G protein of the lab-adapted Pasteur Virus [PV] strain) for 
use as the antigen. The secondary (detection) system was an enzyme conjugated Staphylococcus 
aureus protein A/substrate color reaction. The results were reported in EU/mL (anti-rabies 
glycoprotein level) calculated by comparison of the sample optical density reading against a 
standard curve of positive standards supplied in the kit. 
 RFFIT assay 5.3.6
The serum samples were tested in the RFFIT assay as previously described (Velleca & 
Forrester, 1981). The established RFFIT assay uses CVS-11 as the challenge virus strain. For the 
modified RFFIT assays, the following strains were used: Eastern Pipistrelle, Tadarida, and Flury 
LEP. RVNA titer values were standardized to IU/mL values by comparison with the Standard 
Rabies Immune Globulin (SRIG) (WHO 1st international RIG/Lot R-3 FDA/CBER). 
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 Statistical analysis 5.3.7
 After serological testing was completed, the MFI (bead assay) IU/mL (RFFIT assay) and 
EU/mL (ELISA assay) results were analyzed for comparison of the assays. Result comparison by 
assay and by time point was performed by ANOVA (Analyse-It Software). Method comparison 
tests (Kappa Analyse-it Software) were used to compare the multiplex bead assay with the 
single-plex ELISA and RFFIT assays and to compare the MapPix results between rabies strains 
(Passing-Bablok fit, Analyse-it Software).  Assay precision over a range of analytic 
concentration of equine IgG was determined. The coefficient of variation was calculated for 4 
replicate tests of three samples tested in the same assays for intra-assay precision and eight 
samples tested in 2 independent assays for inter-assay precision analysis.     
 Results 5.4
 Silver Stain of SDS-PAGE 5.4.1
 The SDS-PAGE gel was silver stained to identify the presence of the glycoprotein in the 
rabies antigen preparations. The gel (see Figure 5-1) indicates bands at molecular weight 65 
consistent with the G protein, the immunodominant protein of the rabies virus. 
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Figure 5.1 Silver stain of SDS-PAGE to identify the glycoprotein in the rabies virus antigen 
preparations. 
 
 Confirmation of microsphere antigen coating 5.4.2
 Confirmation of G and N protein from the rabies virus strains binding to the microspheres 
by MagPix assay using the coupled beads and monoclonal antibodies to G and N proteins, both 
monoplex and triplex (performed in duplicate), indicated that both proteins were coupled to the 
beads and that the presence of the other bead sets in the triplex did not interfere with the binding 
of antibody to the proteins. The mean fluorescent intensities (MFIs) for each protein were similar 
in the monoplex and the triplex formats demonstrating compatibility for the multiplex format 
(see Table 5-1). 
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Table 5.1. MFI readings of monoclonal anti-rabies G and N antibodies against rabies antigen 
coated beads tested in monoplex and triplex assays. 
 Antigen 
 
CVS-11 ERA Flury 
Monoplex Anti-G 78 MFI 53 MFI  41 MFI 
Monoplex Anti-N  88 MFI 38 MFI 40 MFI 
Triplex Anti-G 81 MFI 52 MFI  40 MFI 
Triplex Anti-N 67 MFI 32 MFI 33 MFI 
 
 MagPix Assay 5.4.3
 The optimal sample dilution was determined by evaluating the ability to detect antibody 
levels across the range of samples. As seen in Figure 5-2, the 1:2000 serum dilution was better 
able to distinguish differences in the specificities of the antibodies than 1:500 for three horses 
with antibody levels in the high, moderate and low range of the assay. The precision of the Mean 
Fluorescent Intensity (MFI) readings in MagPix assays was determined to range from 2.7% to 
12.2% for intra-assay and from 0.0% to 29.9% for inter-assay (see Table 5-2) for two 
independent assays. It was noted that, as expected, the lowest precision was seen in the samples 
with the lowest MFI readings. Also, noted a third independent assay results were outside this 
precision range. 
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Figure 5.2. MFI readings for three horses (Farrah, Jerry, and Neitto) pre-booster (panel A) and 
post-booster (panel B) samples; and the fold increase MFI (Log) for each (panel C). 
 
The MFI readings for each horse serum sample (pre and post booster vaccination) for the 
microspheres coupled with the wild type rabies strains (Eastern Pipistrelle, North Central Skunk, 
Tadarida, and South Central Skunk) and the lab-adapted rabies strains (ERA, Flury-LEP, and 
CVS-11) varied by rabies strain and by individual horse (see Figure 5-3). The post booster 
antibody responses as measured against the wild type bat and skunk strains in the MagPix assays 
were lower (5-10 fold less) compared to the lab-adapted strains (see Figure 5-3, panel B). One 
horse (Neitto) was found to have a very low antibody response to all the strains in both its pre 
and post serum sample (see Figure 5-3, panels A and B). Examination of the fold-increase in 
MFI between pre and post booster serum samples indicates a non-uniform pattern in the 
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responses to the different strains.  Just over half of the subjects (10 horses or 64%) had the 
highest fold increase in response (MFI) to the lab adapted/vaccine strains; the fold increase was 
highest to ERA strain in most of those (7 horses). Of the horses with their highest rise in rabies 
antibody response specific for the wild type strains, no one strain was prevalent. (See Figure 5-
4). Of the horses with the highest fold antibody level increases to rabies antigens overall (greater 
than 2-fold rise), 75% had their highest fold increase to the lab-adapted/vaccine strains. 
 
Table 5.2. Intra- and inter-assay precision of MFI (log transformed) readings. 
  Sample CVS-11 ERA Flury-LEP E. Pip. NCS Tad. SCS 
Intra-
assay 
precision 
(CV%) 
Luke Pre 1:2000 2.9 3.7 3.1 4.0 6.6 7.6 7.0 
Reggie Pre 1:2000 5.3 7.4 6.7 3.3 5.2 2.7 5.4 
Neitto Pre 1:2000 12.2 11.7 12.0 2.7 5.8 5.6 5.2 
         
Inter-
assay 
precision 
(CV%) 
Luke Pre 1:2000 4.4 3.5 2.9 1.0 4.8 3.9 4.7 
Luke Post 1:2000 6.3 5.9 5.3 3.0 7.5 14.3 7.8 
Reggie Pre 1:2000 1.2 1.0 1.9 16.0 4.0 13.9 6.7 
Reggie Post 1:2000 0.1 0.3 1.1 6.8 1.3 3.3 2.1 
Neitto Pre 1:2000 11.1 15.0 14.3 29.0 27.4 27.4 29.9 
Neitto Post 1:2000 0.6 2.9 2.1 3.5 3.1 12.0 2.8 
Janus Pre 1:2000 4.1 5.2 5.9 14.2 8.6 11.0 10.5 
Janus Post 1:2000 0.5 0.3 0.3 8.5 0.4 1.3 0.0 
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A 
 
B 
 
Figure 5.3. Mean fluorescent intensity readings of the microspheres coated with different rabies 
strains (CVS-11, ERA, Flury-LEP, Eastern Pipistrelle, North Central Skunk, Tadarida, and South 
Central Skunk) tested against the horse sera from 18 horses drawn pre (A) and post (B) rabies 
vaccination. 
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Figure 5.4. The fold-increase (log), defined as the post booster MFI measurement divided by the 
pre booster MFI measurement , for each Magpix assay. 
 
 Assay comparison 5.4.4
 The assays were compared by the ability to detect specific antibody response to rabies 
vaccination; both the individual measurements and the fold increase values were analyzed. Table 
5-3 displays the results of the MagPix assay (CVS-11, ERA, and Flury-LEP as the target 
antigens), RFFIT results (CVS-11 as the challenge virus strain), and ELISA (PV as the target 
antigen). For most horses all three assays were able to detect rise in antibody response (89% of 
the horses had a 10% or greater rise in response by all the assays); for 8 of the 18 horses the 
RFFIT measurement fold-increase was highest, for 7 horses the ELISA measurement fold 
increase was highest, and for 3 horses the MagPix measurement fold increase was highest (see 
Figure 5-5). Of the horses with the highest fold antibody response increase across the different 
assays, the RFFIT fold increase was the highest. 
 The multiplex MagPix assay results are reported in MFI and were not converted to 
standardized units as is done with the RFFIT and the BioRad ELISA antibody measurements. 
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The results for each assay were categorized as positive or negative by the following cut-off 
levels 0.5 IU/mL for RFFIT (as recognized by WHO and OIE for indication of adequate 
response to vaccination), 0.125 EU/mL for ELISA (per the ELISA kit instructions) and MFI 332 
(the mean of all background, and rabies antibody negative control sample MFI readings plus 3 
standard deviations). Using the kappa test for the analysis of agreement between the assays 
(RFFIT, ELISA, and MagPix with CVS-11 as the antigen), categorizing the results as positive or 
negative, produced the following results: RFFIT versus ELISA had a kappa statistic 0.72 
(p<0.0001), RFFIT versus MagPix had a kappa statistic 0.48 (p=0.0008), while the ELISA 
versus MagPix comparison produced a kappa statistic of 0.30 (p=0.0116). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
117 
Table 5.3. Assay results (RFFIT in IU/mL, ELISA in EU/mL, and MagPix in MFI) for the horse 
serum samples drawn pre- and post-booster vaccination.  
    Assay and Rabies Virus Strain (Antigen)   
  
RFFIT ELISA MagPix 
ID Time-point CVS-11 PV CVS-11 ERA Flury-LEP 
Cricket   pre-booster 0.1 0.0625      20,717       18,477       19,112  
Cricket   post-booster 100.0 18.261      25,344       26,884       26,909  
Luke   pre-booster 22.0 1.549      17,137       12,060       15,158  
Luke   post-booster 93.0 4.192      22,371       18,907       21,997  
Crea   pre-booster 11.9 0.671      15,416          8,626       11,894  
Crea   post-booster 125.0 3.639      22,368       16,733       20,512  
Janus   pre-booster 16.0 1.835         3,641          2,369          2,985  
Janus   post-booster 28.0 3.252         8,585          6,302          7,779  
Reggie   pre-booster 0.1 0.0625         1,723             913          1,183  
Reggie   post-booster 5.8 0.439         8,972          5,722          7,293  
Gator   pre-booster 8.0 1.625         4,884          3,877          5,119  
Gator   post-booster 22.0 2.971         8,816          7,556          9,243  
Jag   pre-booster 100.0 3.618         3,905          2,305          4,056  
Jag   post-booster 95.0 15.133         8,534          5,215          8,396  
George   pre-booster 68.0 8.006      17,005       10,916       11,966  
George   post-booster 113.0 14.722      23,346       18,620       20,699  
Blondie   pre-booster 24.0 2.888         3,472          2,396          3,263  
Blondie   post-booster 37.0 3.208      10,326          7,477          9,809  
Gunnie  pre-booster 6.0 0.623         2,246          1,943          1,741  
Gunnie  post-booster 26.0 3.778         2,084          1,817          1,934  
Farrah  pre-booster 20.0 3.253      18,305       24,461       25,479  
Farrah  post-booster 37.0 12.296      19,153       26,447       27,123  
Sunny  pre-booster 26.0 3.899         6,905          5,539          7,425  
Sunny  post-booster 29.0 7.067      10,796          8,665       10,970  
Jerry  pre-booster 11.9 1.698         1,073             799          1,072  
Jerry  post-booster 21.0 10.008         8,162          5,836          8,191  
Neitto  pre-booster 0.1 0.0625            253             214             143  
Neitto  post-booster 0.5 0.0625            626             469             373  
Nacho  pre-booster 0.5 0.0625         2,396          1,513          2,282  
Nacho  post-booster 107.0 3.635      10,412          7,272       10,529  
Fargo  pre-booster 12.3 0.939            444             360             362  
Fargo  post-booster 120.0 17.529            879             635             885  
Coon  pre-booster 2.9 0.899         1,228             752             999  
Coon  post-booster 93.0 5.189         5,706          3,195          4,715  
Josie  pre-booster 105.0 7.435         5,038          2,634          3,610  
Josie  post-booster 120.0 17.315      10,435          5,988          8,156  
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Figure 5.5. The fold increase (log) in antibody measurements for RFFIT (IU/mL), ELISA 
(EU/mL), and MagPix (MFI), calculated for each horse by dividing the post-vaccination result 
by the pre-vaccination result. 
  
Taking all the assay results into consideration (MagPix with all 7 strains, RFFIT, and 
ELISA), there is significant difference between pre-booster and post-booster results (MFI, 
IU/mL and EU/mL, respectively) and between assays, p<0.0001 (2-way ANOVA, Analyse-It 
Software). No significant difference was found between MagPix results (MFI) of CVS-11, ERA, 
and Flury-LEP assays comparing all measurements (pre and post booster vaccination), p=0.6396, 
though a significant difference between the antibody measurements of all samples with wild-type 
strain MagPix assays was found, p=0.0001 (1-way ANOVA analysis, Analyse-It Software).  By 
pairwise (Tukey test at 95% confidence interval) analysis, a significant difference in the results 
between the Eastern Pipistrelle assay and each of the North Central Skunk, Tadarida, and the 
South Central Skunk assays was found. No differences between the assays North Central Skunk 
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versus Tadarida, North Central Skunk versus South Central Skunk, and Tadarida versus South 
Central Skunk pairwise comparisons were determined. 
 Passing and Bablok comparisons between the antibody measurements (MFI) of all 
samples (pre and post booster vaccination) of selected pairs of MagPix assays were performed 
designating the Mag-Pix CVS-11 as the reference assay (see Figure 5-6, panels A to D). The best 
fits obtained were between the lab adapted strains assays. Contrasts between lab-adapted strains 
(ERA and Flury-LEP) and the wild-type strains (E. Pipistrelle and Tadarida, North Central 
Skunk and Tadarida) indicate that though the fit between all lab-adapted strains is better than 
between lab-adapted and wild-type (CVS-11 versus Easter Pipistrelle and versus Tadarida), the 
fit between wild type strains is more varied (see Figure 5-6, panels E, F and G).  
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Figure 5.6. Scatter plot with Passing & Bablok fit of MFI measurements of selected MagPix 
assays. 
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 Comparison of strain difference in neutralizing antibody measurement 5.4.5
 The paired samples (pre and post booster vaccination) from six horses were evaluated for 
RVNA level in modified RFFIT assays using one lab-adapted, vaccine strain and two wild-type 
strains in place of CVS-11 as the challenge virus. The results obtained were compared against 
the results (IU/mL) obtained for the established RFFIT assays using CVS-11 for differences or 
trends between viruses, between horses, and between assays. In the modified RFFIT assays, 
though all horses but one (Crea), in both pre and post booster samples, had highest IU/mL results 
to the Flury-LEP strain and all except one (Josie) had lowest IU/mL results to Tadarida (see 
Table 5-4), the fold increase in results were quite varied. No established pattern of strain with the 
highest or lowest rise in RVNA was identified (see Figure 5-7). In addition, evaluation for trends 
between the modified RFFIT assay results and the MagPix assay results with the different rabies 
virus strains demonstrated that for some horses the relationship of the log transformed fold 
increase (highest to lowest responses to the strains) in the two assay types were different, see 
Figure 5-8, Luke and Crea; while for other horses similar fold increases were measured for the 
strains in both assays, see Figure 5-8, Neitto and Josie. 
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Table 5.4. RVNA (IU/mL) results obtained from modified RFFIT assays using different rabies 
strains as the challenge virus for six paired horse samples. 
 
            
  
RFFIT modified RFFIT/Challenge Virus 
ID Time-point CVS-11 Flury-LEP E. Pipistrelle Tadarida 
Cricket   pre-booster 0.1 0.4 1.0 0.1 
Cricket   post-booster 100.0 390.9 252.9 38.2 
Josie  pre-booster 105.0 467.5 163.0 65.4 
Josie  post-booster 120.0 955.9 598.1 250.0 
Crea   pre-booster 11.9 16.4 19.3 7.7 
Crea   post-booster 125.0 93.5 64.5 22.4 
Gator   pre-booster 8.0 73.2 34.4 10.7 
Gator   post-booster 22.0 61.2 40.9 13.1 
Neitto  pre-booster 0.1 0.1 0.1 0.1 
Neitto  post-booster 0.5 3.4 2.5 0.5 
Luke   pre-booster 22.0 38.2 37.9 13.6 
Luke   post-booster 93.0 109.9 82.5 62.7 
 
 
 
Figure 5.7. Fold increase in IU/mL results in modified RFFIT assays using different rabies 
strains as the challenge virus. 
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Figure 5.8. Fold increase in IU/mL (RFFIT) and MFI (MagPix) after log transformation for 
different rabies strains as the challenge virus or antigen, respectively. 
 
 Discussion 5.5
 Horses, as are all mammals, are susceptible to rabies.  Although the number of rabies 
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domestic animals by rabies vaccination coverage has resulted in the majority of reported rabies 
cases in the U.S. to be found in wildlife species. The incidence of rabies in domestic species 
follows that of wildlife species; when there are high numbers of rabies in wildlife there is greater 
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
RFFIT MagPix
Josie  
0.00
0.50
1.00
1.50
2.00
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
RFFIT MagPix
Neitto  
0.00
0.20
0.40
0.60
0.80
1.00
1.20
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
RFFIT MagPix
Crea  
0.00
0.10
0.20
0.30
0.40
0.50
0.60
0.70
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
C
V
S-
1
1
Fl
u
ry
-L
EP
E.
 P
ip
.
Ta
d
ar
id
a
RFFIT MagPix
Luke  
124 
probability of rabies in domestic species. The majority of horses live outside exposed to wildlife 
species. Horses are naturally curious, investigating wildlife in their surroundings. Rabies 
vaccination produces a polyclonal response known to neutralize in vitro and protect against in 
vivo the different rabies virus strains within rabies geneotype 1 (classical rabies), including 
variants found in wildlife within the United States (Lodmell, Smith, Esposito, & Ewalt, 1995). 
Even so, a dissimilarity in antibody response and effective protection between species, mice and 
guinea pig, given a standard rabies vaccine and challenged with the street rabies virus variants 
has been demonstrated (Wiktor, 1985). Also, a variation immune response conferred by two 
rabies vaccine parent strains, PM and ERA, was found in mice after challenge with a Polish Bat 
strain of the rabies virus (Dietzschold, Tollis, Rupprecht, Celis, & Koprowski, 1987). Though 
these experimental findings indicate a potential variance in protection afforded by vaccine strains 
to street (or wild-type) strains no evidence exists for true vaccine failures (Smith, 2002). For 
rabies biologics, the ability to provide/stimulate effective immunity to cover all rabies virus 
variants present in the environment for the target species is paramount. 
 Measurement of the immune response to vaccination can be undertaken by various 
laboratory techniques. The use of microarray assays is particularly attractive to investigate 
antibody responses to multiple antigens because of the reduction of sample volume and time 
requirements compared to conventional antigen-antibody assays. Microarray assays such as 
bead-based multiplex assays have been used for serology for various infectious agents (Andrade 
et al., 2014; Michel, Pawlita, Boeing, Gissmann, & Waterboer, 2014). In this study, the utility of 
a microarray (MagPix) assay for investigation of specific antibody response to rabies virus 
variants, both vaccine (lab adapted) and wild-type strains as generated by routine rabies booster 
vaccination in horses was evaluated and compared to established procedures, RFFIT and ELISA.  
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 The ability of the MagPix assay to detect a rise in specific antibody response to both the 
vaccine strains and the wild-type strains was demonstrated. The horses were given a booster 
vaccination with a vaccine strain (PV) closely related to ERA (see Figure 5-9). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-9. A phylogenetic tree of the G protein homology relationships between the vaccine/lab 
adapted and wild-type rabies virus strains. 
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Clearly there was a lower response against the wild-type strains than the lab adapted strains in 
this assay. It has been found that pathogenic (wild-type) strains differ from apathogenic or 
attenuated strains in the expression of glycoprotein; pathogenic strains express less G protein 
than attenuated strains which allows the pathogenic strains to effectively spread through synaptic 
junctions and to avoid apoptosis (Morimoto, Hooper, Spitsin, Koprowski, & Dietzschold, 1999; 
Yan et al., 2001). Infection in mice with apathogenic rabies virus generates higher titers of 
RVNA than pathogenic rabies virus (Wiktor et al., 1978). A study to determine the effect of 
increasing or decreasing the G protein expression while maintain the same G protein sequence by 
codon optimization or de-optimization, respectively found that a 2-fold increase in expression 
resulted in decrease pathogenicity in mice indicating that degree of expression, not just sequence 
of the G protein affects actions of the virus (Wirblich & Schnell, 2011). It is possible that the 
difference in G protein expression of the wild-type viruses in the MagPix assays caused the 
decrease in measurement of specific antibody at least in part or combination with the difference 
in G protein epitopes. 
 Analysis of the MagPix assays results by Passing and Bablok demonstrate a closer 
agreement between the results obtained with the lab adapted strains, CVS-11, Flury-LEP, and 
ERA, as expected from the sequence relationships (see Figure 5-6 and 5-9). The agreement 
between the results obtained in the Eastern Pipistrelle and Tadarida MagPix assays is not as close 
given their less homologous G sequence relationship. Conversely, the agreement of response as 
measured by the Tadarida and North Central Skunk MagPix assays was nearly as good as 
between the lab-adapted strains indicating that homology in genetic relationship may not be the 
best indication of the antigenic relationship. It is interesting to note that for the majority of horses 
the highest increase in antibody response was measured in the ERA MagPix assay and that the 
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ERA strain is most closely related to the PV strain of the vaccine used for the booster 
vaccinations (see Figure 5-9). Evidence for G sequence variation or epitope difference resulting 
in a quantitatively immune response difference is difficult to distinguish. An effort to associate 
antigenic distances as determined by rabies serology to rabies virus glycoprotein sequence was 
undertaken by Horton et al (Horton et al., 2010); the findings conclude that the genetic and 
antigenic distances did not correlate as consistently as expected. Using sequence data to 
determine effectiveness of a vaccine strain in eliciting protective antibodies against wild-type 
strains is not entirely warranted. An interesting finding in the Horton study was that the same 
antigenic variation was determined whether the sources of antibodies were human, rabbit, or 
mouse signifying that species difference was not a factor. 
 The results of vaccine response measurement against different rabies strains by MagPix 
compared to RFFIT, underscores that the functional action of the antibody response cannot be 
interpreted from the quantification of the response by level of binding antibody. In all the horse 
sera measured for vaccine response by both modified RFFIT and MagPix, there was a smaller 
difference in neutralizing antibody measurement values (IU/mL) between the lab adapted strains 
and the wild-type strains than the binding antibody measurement values (MFI) by MagPix 
between the two types of strains. This indicates that though there was 5-10 fold less binding 
antibody (as detected by the MagPix assays), the ability to neutralize the virus was not 
diminished to the same degree. In at least two samples (Cricket and Crea, pre-booster samples) 
the neutralizing ability was higher to a wild-type than to a lab adapted strain, see table 5-4. 
This study had a number of limitations. The lack of complete vaccination history for all 
horses limited the evaluation of the relationship of vaccine strain to the primary specificity of the 
antibodies produced as well as the effect of multiple vaccinations or use of different rabies 
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vaccines strains used in primary and subsequent vaccinations. The use of purified rabies 
glycoprotein rather than whole rabies virus as the antigen on the microspheres may have allowed 
better discernment of the antibody specificities and eliminated the possible confounding factor of 
degree of G protein expression.  In addition, purified antigen or establishment of stable antigen 
preparation may increase the precision of the assay. Quantitative measurement of the antibody 
responses by relating the MFI to total IgG in the serum would standardize the results for 
enhanced evaluation of the response over time, between horses, and between assay runs, and 
allow assessment of the assay accuracy. 
  Conclusions 5.6
The results of this study demonstrate the utility of using a multiplex MagPix assay to 
measure the antibody response to rabies booster vaccination. The ability to separately analyze the 
specificities involved in the polyclonal response for evaluation of the vaccination coverage of 
rabies variants existing in nature was also verified. The assay has adequate precision as is 
expected for ligand based assays (2001). Agreement of results to established methods, RFFIT 
and ELISA is good as defined by the kappa test for this set of samples, while at the same time 
differences based on the particular aspect of the antibody response is measured by each assay 
was evident. The ELISA assay and the MagPix assay both detect binding antibody of the IgG 
subclass, while RFFIT measures the neutralizing ability of antibodies of all subclasses that may 
be produced to rabies vaccination and present in the serum (primarily IgG and IgM). 
 Vaccinated horses have succumbed to rabies, in some cases the horses had a RVNA level 
below 0.5 IU/mL as in a challenge study (Hudson, Weinstock, Jordan, & Bold-Fletcher, 1996) 
and in other instances the RVNA level was unknown as in a review of rabies cases in horses 
from 1970 to 1990 (Green, Smith, Vernau, & Beacock, 1992). The ability to easily check the 
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antibody response level in vaccinated horses would ensure individual horse maintains adequate 
protection from rabies exposure in their environment. Because the most likely exposures are to 
come from encounters with rabid wildlife, laboratory tests that can differentiate antibody 
specificities produced after rabies vaccination and identify weak responses to a particular strain 
would alert owners and veterinarians to a possible risk of rabies infection. 
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